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Abstract The autosomal dominant neuronal ceroid lipofuscinoses (NCL) CLN4 is caused by
mutations in the synaptic vesicle (SV) protein CSPa. We developed animal models of CLN4 by
expressing CLN4 mutant human CSPa (hCSPa) in Drosophila neurons. Similar to patients, CLN4
mutations induced excessive oligomerization of hCSPa and premature lethality in a dose-
dependent manner. Instead of being localized to SVs, most CLN4 mutant hCSPa accumulated
abnormally, and co-localized with ubiquitinated proteins and the prelysosomal markers HRS and
LAMP1. Ultrastructural examination revealed frequent abnormal membrane structures in axons and
neuronal somata. The lethality, oligomerization and prelysosomal accumulation induced by CLN4
mutations was attenuated by reducing endogenous wild type (WT) dCSP levels and enhanced by
increasing WT levels. Furthermore, reducing the gene dosage of Hsc70 also attenuated CLN4
phenotypes. Taken together, we suggest that CLN4 alleles resemble dominant hypermorphic gain
of function mutations that drive excessive oligomerization and impair membrane trafficking.
DOI: https://doi.org/10.7554/eLife.46607.001
Introduction
NCLs comprise a group of progressive neurodegenerative diseases with 14 known disease-associ-
ated genes, termed CLN1-14 (Haltia, 2003; Haltia and Goebel, 2013; Jalanko and Braulke, 2009;
Mole and Cotman, 2015). NCLs have mostly an infantile or juvenile symptomatic onset and are
characterized by loss of vision, gait abnormalities, seizures, dementia, and premature death. In gen-
eral, NCLs are considered lysosomal storage diseases due the accumulation of lipofuscin and are
typically caused by recessive loss of function mutations with one exception, CLN4. Accordingly, lyso-
somal dysfunction, dysregulated ER-lysosomal trafficking, or aberrant lipid modifications are thought
to be the basis for most NCLs, consistent with the known function of the mutated genes
(Bennett and Rakheja, 2013; Ca´rcel-Trullols et al., 2015; Mole and Cotman, 2015; Warrier et al.,
2013). Understanding disease mechanisms of NCLs has implications as well for more prevalent dis-
eases since mutations in a growing number of CLN genes also cause other diseases like frontotem-
poral lobar degeneration, progressive epilepsy with mental retardation, spinocerebellar ataxia,
retinitis pigmentosa, juvenile cerebellar ataxia, or Parkinson disease 9 (Bras et al., 2012; Mole and
Cotman, 2015; Yu et al., 2010).
Imler et al. eLife 2019;8:e46607. DOI: https://doi.org/10.7554/eLife.46607 1 of 34
RESEARCH ARTICLE
The autosomal dominantly inherited NCL CLN4 has an adult onset between 25 and 46 years.
CLN4 is caused by either the amino acid (aa) substitution L115R or the single amino acid deletion
L116D in the SV protein CSPa, which is encoded by the human DNAJC5 gene (Benitez et al., 2011;
Cadieux-Dion et al., 2013; Noskova´ et al., 2011; Velinov et al., 2012). CSPa is unique among
NCL-associated genes since it encodes a SV protein with no known lysosome-associated functions.
Accordingly, there is no CLN4 model explaining lysosomal failure.
CSPa is an evolutionary conserved neuroprotective co-chaperone of Hsc70 and required to main-
tain synaptic function and prevent neurodegeneration (Burgoyne and Morgan, 2011;
Burgoyne and Morgan, 2015; Zinsmaier, 2010). Gene deletions in flies and mice cause progressive
locomotor defects, paralysis and premature death due to neurodegeneration (Chandra et al., 2005;
Ferna´ndez-Chaco´n et al., 2004; Umbach et al., 1994; Zinsmaier, 2010; Zinsmaier et al., 1994).
On SVs, CSPa forms a molecular chaperone complex with Hsc70 for a selected set of clients, which
include SNARE proteins and dynamin (Chandra et al., 2005; Nie et al., 1999; Sharma et al., 2012;
Sharma et al., 2011; Zhang et al., 2012). Maintaining SNARE and dynamin function is likely key to
CSP’s neuroprotective role (Burgoyne and Morgan, 2011; Rozas et al., 2012; Sharma et al., 2012;
Sharma et al., 2011).
The CLN4 causing dominant mutations L115R and L116D are clustered in the palmitoylated cyste-
ine-string (CS) domain of CSPa, which mediates CSPa’s secretory trafficking to axon terminals, its SV
association, and its dimerization (Arnold et al., 2004; Chamberlain and Burgoyne, 1998;
Greaves and Chamberlain, 2006; Greaves et al., 2008; Ohyama et al., 2007; Stowers and Isacoff,
2007; Swayne et al., 2003). Palmitoylation of the CS domain enables CSPa’s export from the ER
and Golgi (Chamberlain and Burgoyne, 1998; Greaves and Chamberlain, 2006; Greaves et al.,
2008; Ohyama et al., 2007; Stowers and Isacoff, 2007). Palmitoylation must then be maintained
for CSPa’s association with synaptic vesicle precursors (SVPs) and/or SVs, presumably to due to the
short lifetime of palmitoylation (Fukata and Fukata, 2010). The latter has been indicated by much
reduced synaptic levels of CSP in loss of function mutants of the synaptic palmitoyl-transferase
HIP14/DHHC17 (Ohyama et al., 2007; Stowers and Isacoff, 2007). Notably, there is a link between
CSPa’s degree of lipidation and lysosomal dysfunction. In a lysosomal disease mouse model of
Mucopolysaccharidosis type IIIA (MPS-IIIA), palmitoylation of CSPa was decreased and its proteaso-
mal degradation was increased (Sambri et al., 2017). Since overexpression (OE) of CSPa in MPS-IIIA
mice ameliorated their presynaptic defects, neurodegeneration, and prolonged survival, CSPa could
be a critical factor for the progression of many lysosomal diseases (Sambri et al., 2017).
Post-mortem analysis of CLN4 patient brains suggests that dominant CLN4 mutations have two
key pathological effects: to reduce monomeric levels of lipidated CSPa and promote the formation
of high-molecular weight CSPa protein aggregates/oligomers that are ubiquitinated (Greaves et al.,
2012; Henderson et al., 2016; Noskova´ et al., 2011). Similar effects of the mutations were seen in
HEK293T, PC12 cells, and fibroblasts from CLN4 carriers (Benitez and Sands, 2017; Greaves et al.,
2012; Zhang and Chandra, 2014). In vitro, CLN4 mutant CSPa aggregates form in a time-, concen-
tration- and temperature-dependent manner (Zhang and Chandra, 2014). Palmitoylation of CSPa
promotes aggregation (Greaves et al., 2012), although it is not essential (Zhang and Chandra,
2014). In addition, post-mortem brains of CLN4 patients exhibit large scale changes in protein pal-
mitoylation (Henderson et al., 2016). CLN4 mutations have no adverse short-term effects on CSPa’s
co-chaperone functions in vitro, including activation of Hsc70’s ATPase activity, or the binding to
chaperone clients like SNAP25 and dynamin (Zhang and Chandra, 2014). However, during pro-
longed incubation, the ability of mutant CSPa to stimulate Hsc70’s ATPase activity declines consider-
ably (Zhang and Chandra, 2014).
Several mechanisms of CLN4-induced neurodegeneration have been suggested. As with other
neurodegenerative diseases, progressive aggregation of mutant CSPa alone may account for the
dominant nature of CLN4 mutations (Greaves et al., 2012; Henderson et al., 2016; Noskova´ et al.,
2011; Zhang et al., 2012). In turn, this may progressively deplete total CSPa levels such that it
causes a haplo-insufficiency that triggers neurodegeneration (Greaves et al., 2012; Noskova´ et al.,
2011; Zhang and Chandra, 2014). Consistent with this possibility, one-year old heterozygous CSPa
KO mice develop a moderate motor defect that is characterized by a reduced ability to sustain
motor unit recruitment during repetitive stimulation (Lopez-Ortega et al., 2017). Alternatively,
aggregating CSPa may have a dominant-negative effect and sequester WT CSPa (Greaves et al.,
2012; Henderson et al., 2016; Zhang et al., 2012). However, the link between CLN4 mutations,
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lysosomal dysfunction and neurotoxicity remains unclear. Therefore, an animal model may provide
critical insight into molecular and cellular mechanisms underlying CLN4 disease.
Here, we generated two Drosophila models for CLN4 by expressing either CLN4 mutant hCSPa
or dCSP in fly neurons. The humanized fly model has the unique advantage of being able to differen-
tially visualize CLN4 mutant hCSPa and WT dCSP. We show that both fly models replicate all key
pathogenic biochemical properties of CLN4, including decreased monomeric CSP levels, increased
levels of high-molecular weight, and ubiquitinated CSP oligomers. Further analysis revealed novel
insights into mechanisms underlying CLN4 pathology.
Results
Generation of a Drosophila CLN4 model
We generated a Drosophila model of CLN4 by expressing the disease-causing human proteins
hCSPa-L115R, hCSPa-L116D (Figure 1A; denoted as L115 and L116 from now on) and the corre-
sponding WT hCSPa control from a common genomic phi31-attP insertion site under the transcrip-
tional control of the yeast Gal4-UAS expression system (Brand and Perrimon, 1993). Unless
Figure 1. Generation of a Drosophila CLN4 model. (A) Structure of CSP and position of CLN4 mutations in
the cysteine-string (CS) domain of hCSPa and dCSP. CSP’s N-terminal J domain, linker domain and C-terminus are
indicated. (B) Larval VNC of animals expressing WT hCSPa in neurons from a single transgene with an elav driver
immunostained for hCSPa and endogenous dCSP. Scale bar, 20 mm. (C) Larval NMJs of control and animals
expressing WT hCSPa immunostained for hCSPa, dCSP, and HRP marking the presynaptic plasma membrane.
Scale bar, 5 mm. (D) Adult lifespan of control (dcspX1/+, black), cspX1/R1 deletion mutants (green) and cspX1/R1
mutants expressing WT hCSPa (blue), hCSP-L115, (orange), hCSPa-L116 (red), or dCSP2 (purple) with an elav
driver.
DOI: https://doi.org/10.7554/eLife.46607.002
The following figure supplement is available for figure 1:
Figure supplement 1. Phenotypic effects of CLN4 mutations.
DOI: https://doi.org/10.7554/eLife.46607.003
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otherwise indicated, we used the pan-neuronal elav-Gal4 driver C155 (Lin and Goodman, 1994) to
express these proteins exclusively in otherwise WT neurons (w1118).
To evaluate whether WT hCSPa is at least partially functional in fly neurons, we first determined
whether neuronally expressed hCSPa is properly palmitoylated and targeted to SVs. This analysis
was aided by the availability of species-specific antibodies that discriminate between hCSPa and
dCSP (Figures 1B–C and 2A; Figure 1—figure supplement 1A). Neuronally expressed hCSPa was
efficiently trafficked to axon terminals and co-localized with endogenous dCSP in the neuropil of the
larval ventral nerve cord (VNC; Figure 1B) and larval neuromuscular junctions (NMJs; Figure 1C).
Consistent with the normal trafficking of hCSPa, the majority of neuronally expressed hCSPa was
palmitoylated, which was confirmed by treating larval protein extracts with 0.5 M hydroxylamine
(Figure 1—figure supplement 1A).
Figure 2. CLN4 mutations cause dose-dependent oligomerization of hCSPa in neurons. WT and mutant hCSPa (L115/L116) were expressed in larval
neurons of white1118 animals (control) with an elav driver from one or two transgenes (2x). (A) Western blot of larval brain protein extracts probed for
hCSPa. Signals for SDS-resistant hCSPa oligomers (OM), lipidated monomeric hCSP (LM), and non-lipidated hCSP (NLM) are indicated. b-tubulin was
used as loading control. (B) Western blots probed for hCSPa or lysine-linked-ubiquitin of hCSPa-immunoprecipitated extracts from adult heads of
indicated genotypes. Signals for IgG heavy chain are indicated. (C) Average oligomer/monomer ratios (N = 5). (D–F) Levels of lipidated (D), non-
lipidated (E), and total hCSPa (F) normalized to WT hCSPa (N = 6). (G–I) Dosage-dependent increase of hCSPa oligomer (G), lipidated (H), and non-
lipidated monomer levels (I). Signals were normalized to loading control and plotted as n-fold change from 1-copy expression of WT hCSPa (N = 6). (J)
Levels of monomeric dCSP shown as n-fold change from control (N = 3). Graphs display mean ± SEM. Statistical analysis used one-way ANOVA (C–F, J)
or two-tailed unpaired t test (G–I); *, p<0.05; **, p<0.01; ***, p<0.001.
DOI: https://doi.org/10.7554/eLife.46607.004
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Next, we tested whether hCSPa can functionally replace endogenous dCSP and restore the pre-
mature lethality of flies lacking dCSP (Zinsmaier et al., 1994). Flies and mice lacking CSP due to a
gene deletion exhibit progressive neurodegeneration, paralysis and premature death (Ferna´ndez-
Chaco´n et al., 2004; Zinsmaier et al., 1994). Pan-neuronal elav-driven expression of normal hCSPa
from one transgenic copy in homozygous dcsp deletion mutants significantly restored adult lifespan
from ~4–5 days to 15–20 days (LD50 p<0.001; Figure 1D). In comparison, expression of fly dCSP2
also restored adult lifespan only partially (Figure 1D). Even though this rescue was only partial, it
confirms that hCSPa is functional in flies, which made a CLN4 Drosophila model using human pro-
teins tenable.
Notably, neuronal expression of hCSP-L115 and -L116 in a dcsp null background was able to par-
tially rescue the lifespan deficit (p<0.001, LD50), although not nearly to the extent of WT hCSPa
(Figure 1D). This indicates that CLN4 mutant hCSPa proteins are at least partially functional.
CLN4 mutations cause formation of SDS-resistant and ubiquitinated
hCSPa protein oligomers in neurons
In humans, CLN4 mutations reduce levels of lipidated monomeric hCSPa and drive the formation of
high-molecular weight, SDS-resistant hCSPa protein oligomers that are ubiquitinated (Benitez et al.,
2015; Greaves et al., 2012; Henderson et al., 2016; Noskova´ et al., 2011). Both features were
also present when mutant hCSP-L115 or -L116 were expressed in non-neuronal and neuronal mam-
malian cell cultures with L115 exhibiting stronger effects than L116 (Diez-Ardanuy et al., 2017;
Greaves et al., 2012; Henderson et al., 2016; Zhang and Chandra, 2014).
To test whether expression of CLN4 mutant hCSPa in Drosophila neurons recapitulates the path-
ological features of post-mortem human brains, we analyzed the properties of CLN4 mutant hCSPa
by immunoblotting, using protein extracts from larval VNCs. When expressed from a single trans-
gene with an elav-Gal4 driver, lipidated monomeric protein levels of WT hCSPa were estimated to
be 0.98 ± 0.23 times of endogenous dCSP levels (data not shown). In comparison, levels of lipidated
monomeric hCSP-L115 and -L116 were significantly reduced to 13% and 40% of WT hCSPa levels,
respectively (p<0.003, Figure 2A,D). Levels of lipidated hCSP-L115 monomers were significantly
lower than hCSP-L116 (p<0.01, Figure 2D). Levels of non-lipidated monomeric hCSP-L115 and -
L116 were comparable to WT hCSPa levels (p>0.2; Figure 2A,E).
Both CLN4 mutations induced the formation of SDS-resistant, high-molecular weight hCSPa
oligomers in Drosophila neurons (p<0.002; Figure 2A,C). In contrast, WT hCSPa oligomers were
barely detectable (Figure 2A,C). The mutation L115 triggered oligomerization to a significantly
larger degree than L116 (p<0.006; Figure 2C), which is consistent with the lower levels of hCSP-
L115 monomers (Figure 2D). Increasing levels of DTT in the buffer to reduce disulfide bonds had lit-
tle to no effect on the levels and size of hCSP-L115 and -L116 oligomers, which varied widely
from ~250 kDa to more than 500 kDa (not shown).
To determine whether CLN4 mutant hCSPa oligomers are ubiquitinated, we immunoprecipitated
hCSPa from larval brain cell lysates and probed western blots with an antibody that specifically
detects K29-, K48-, and K63-linked mono- and poly-ubiquitinated proteins but not free ubiquitin
monomers (Fujimuro et al., 1994). hCSPa antibodies immunoprecipitated both hCSPa monomers
and oligomers (Figure 2B) but not endogenous dCSP (not shown). The anti-ubiquitinated protein
antibody only recognized a strong ~250 kD protein band in precipitates from L115 and L116 mutant
brains, which correlated in size with high-molecular weight hCSPa oligomers (Figure 2B). No ubiqui-
tin-positive signals corresponding to CLN4 mutant hCSPa monomers, WT hCSPa monomers or
oligomers were detected (Figure 2B). Taken together, these data suggest that expression of CLN4
mutant hCSPa in fly brains reproduces the critical biochemical pathological features of post-mortem
human CLN4 brains (Greaves et al., 2012; Henderson et al., 2016; Noskova´ et al., 2011).
Oligomerization of CLN4 mutant hCSPa is dose-dependent
Oligomerization of purified CLN4 mutant hCSPa proteins is dose-dependent in vitro (Zhang and
Chandra, 2014). To test whether this is also the case in vivo, we doubled the gene dosage of WT
and CLN4 mutant hCSPa by expressing two copies of the respective transgenes with a single elav-
Gal4 driver. In comparison to the expression from one transgene, levels of lipidated and non-lipi-
dated monomeric WT hCSPa increased ~2.4 fold and ~3.3 fold, respectively (p<0.01, Figure 2A,D–
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E,H–I). Yet, WT hCSP oligomer levels increased only 1.5-fold (p<0.005; Figure 2G) and remained
low such that the oligomer/monomer ratio was not altered (p=0.9; Figure 2C).
In comparison to single copy gene expression, doubling gene dosage increased levels of lipi-
dated hCSP-L115 monomers only modestly by 1.5-fold (p<0.04) while hCSP-L116 levels were not sig-
nificantly affected (p=0.3; Figure 2H). However, levels of hCSP-L115 and -L116 oligomers increased
4.6- and 3.6-fold, respectively (p<0.04; Figure 2G). Due to the disproportional increase of CLN4
mutant oligomers, the oligomer/monomer ratio increased from 0.9 to 2.8 for hCSP-L115 and from
0.4 to 1.8 for hCSP-L116 (Figure 2C). Hence, oligomerization of hCSP-L115 and -L116 is dose-
dependent.
Doubling expression disproportionally increased levels of non-lipidated hCSP-L115 and -L116
monomers 8.6- and 4.6-fold, respectively (p<0.002, Figure 2I). The increase of non-lipidated mutant
monomers is unlikely due to a rate limiting effect on mechanisms mediating palmitoylation because
levels of non-lipidated WT monomers increased much less than mutant monomers, even though
overall levels of lipidated WT monomers were much higher (Figure 2E).
Doubling gene dosage of hCSP-L115 and -L116 expression increased total overall protein levels
3.0 and 3.9-fold, respectively (p<0.002; Figure 1—figure supplement 1D). It also preserved the rel-
ative difference in overall protein levels between WT and CLN4 mutants (Figure 2F). Since lipidated
mutant monomer levels remained unaltered (p>0.1; Figure 2D), the increase in overall protein levels
of CLN4 mutant hCSPa is essentially due to increased levels of oligomers and non-lipidated mono-
mers (p<0.03; Figure 2C,E).
Levels of endogenous dCSP monomers were not affected by low or high expression of CLN4
mutant hCSPa (Figure 2J). Notably, high-molecular weight oligomers of endogenous WT dCSP
were not detectable after expression of CLN4 mutant hCSPa (Figure 1—figure supplement 1C),
which contrasts a previous study detecting small amounts of overexpressed GFP-tagged WT hCSPa
in CLN4 mutant hCSPa oligomers (Greaves et al., 2012).
Oligomerization of neuronally expressed CLN4 mutant hCSPa precedes
lethality
Elav-driven neuronal expression of WT or CLN4 mutant hCSPa from a single transgene had no effect
on viability during development (Figure 3A) and adult lifespan (not shown). However, doubling
gene expression levels severely reduced viability during development of hCSP-L115 and -L116 ani-
mals in comparison to WT hCSPa expression (p<0.0001; Figure 3A). Adult L115- and L116-mutant
escapers were initially sluggish in comparison to WT hCSPa but improved within ~10 days and exhib-
ited a normal lifespan (not shown), which may be due to a decrease in the elav-driven expression.
There was no significant difference in the viability between L115 and L116 mutant animals (p=0.91;
Figure 3A). The sharp drop in viability induced by 2-copy expression of hCSP-L115 and -L116 indi-
cates a tight threshold of neurotoxicity, which might be linked to the more than 3.6-fold increase of
Figure 3. CLN4 mutations cause dose-dependent lethality and eye degeneration. (A) Viability of animals expressing WT, L115, or L116 mutant hCSPa
pan-neuronally from one or two transgenes (2x) with an elav driver (N  3, n  740). (B) Images of adult fly eyes expressing WT hCSPa or hCSPa-L116
with a GMR-Gal4 driver at 23˚C and 28˚C. (C) Semi-quantitative assessments of CLN4-induced eye phenotypes (N  9). Graphs display mean ± SEM.
Statistical analysis used one-way ANOVA (A) and Kruskal-Wallis test (C); *, p<0.05; **, p<0.01; ***, p<0.001.
DOI: https://doi.org/10.7554/eLife.46607.005
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CLN4 mutant CSPa oligomers and/or the more than 4.6-fold increase of non-lipidated monomers
(Figure 2G,I).
Expression of CLN4 mutant hCSPa with the pan-neuronal nSyb-Gal4 driver also caused a dose-
dependent lethality, which was similar to that of the elav-Gal4 driver (data not shown). In contrast to
the elav-driven expression, CLN4 mutant adult escapers were very sluggish and hardly moved. They
were also unable to properly inflate their wings (Figure 1—figure supplement 1B) and died prema-
turely within 1–3 days.
To further examine potential degenerative effects in adults, we exclusively expressed hCSP-L116
in the eye by using the eye-specific GMR-Gal4 driver (Hay et al., 1997). High-level expression of WT
hCSPa from a line with multiple transgene insertions (see Materials and methods) had essentially no
effect at 23˚C or 28˚C in comparison to non-expressing control (p>0.9; Figure 3B–C). In comparison,
expression of hCSP-L116 at 23˚C severely impaired the size, integrity, and pigmentation of the eye
(p<0.0001; Figure 3B–C). Raising flies at 28˚C to increase Gal4 activity and thereby gene expression
enhanced the severity of the degenerative phenotype of L116-mutant eyes (p<0.0001; Figure 3B–
C). This enhancement correlates with the dose-dependent increase in hCSP-L116 oligomerization
(Figure 2C,G) but the higher temperature may also increase misfolding and/or oligomerization of
mutant hCSPa.
CLN4 mutations impair hCSPa’s synaptic localization
Previously, it has been suggested that CLN4 mutations may disrupt anterograde trafficking of CSPa
due to either oligomer formation or impaired palmitoylation of monomers (Benitez et al., 2011;
Greaves et al., 2012; Noskova´ et al., 2011). However, whether CLN4 mutations indeed affect the
synaptic localization of CSPa remained unclear. To assess this, we triple-immunostained 3rd instar
larval NMJs with antibodies against hCSPa, endogenous dCSP marking SVs, and HRP marking the
neuronal plasma membrane. In comparison to WT hCSPa, levels of mutant hCSP-L115 and -L116
were significantly reduced at synaptic boutons (p<0.013; Figure 4A,H). Expression of CLN4 mutant
or WT hCSPa had no effect on synaptic levels of endogenous WT dCSP at NMJs (p>0.6; Figure 4A,
I). Despite the reduced synaptic levels, mutant hCSPa still partially rescued the lifespan deficit of
dcsp deletion mutants, although not nearly to the extent of WT hCSPa (Figure 1D). This indicates
that CLN4 mutant hCSPa proteins are at least partially functional.
While hCSPa co-localized with endogenous dCSP uniformly in the periphery of synaptic boutons
(Figure 4A,C), hCSP-L115 and -L116 were enriched in brightly stained clusters that were more dis-
tant from the presynaptic membrane (Figure 4A,C). In comparison to control, CLN4 mutant hCSPa
also accumulated abnormally in axons of segmental nerves (Figure 4G) and the larval brain
(p<0.009; Figure 4B,J; Figure 4—figure supplement 1A). The size of CLN4 mutant hCSPa accumu-
lations in the larval brain was heterogeneous, ranging from ~500 nm in diameter to ~3 mm. Occasion-
ally, extreme accumulations of mutant hCSPa were observed at synaptic boutons of larval NMJs
(Figure 4—figure supplement 1C). The occurrence of abnormal hCSP-L115 and -L116 accumula-
tions was dose-dependent (not shown), which was most pronounced in axons of segmental nerves
(Figure 4G). Hence, CLN4 mutations reduce synaptic levels of hCSPa and cause a severe
mislocalization.
Abnormal accumulations of CLN4 mutant hCSPa contain WT dCSP and
ubiquitinated proteins
A fraction of the abnormal accumulations of hCSP-L115 and -L116 in axons (not shown) and somata
(Figure 4E and Figure 4—figure supplement 1A) contained significant amounts of endogenous WT
dCSP. Since WT dCSP was not detected together with high-molecular weight oligomers of CLN4
mutant hCSPa on Western blots (Figure 1—figure supplement 1C), this indicates that CLN4 mutant
hCSPa and WT dCSP may co-accumulate on intracellular membranes.
Theoretically, CLN4 mutant hCSPa could accumulate on ER, Golgi, or abnormal SVP membranes
during secretory trafficking. Alternatively, mutant hCSPa could accumulate on endosomal mem-
branes that are targeted for degradation. To test whether mutant hCSPa accumulations contain
ubiquitinated proteins indicative of prelysosomal membranes, we used antibodies that exclusively
detect ubiquitinated proteins but not monomeric ubiquitin (Fujimuro et al., 1994). Indeed, essen-
tially all CLN4 mutant hCSPa accumulations were immunopositive for ubiquitinated proteins in
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Figure 4. CLN4 mutations reduce synaptic hCSPa levels and cause abnormal accumulations with endogenous dCSP and ubiquitinated proteins in
axons and somata. WT, L115 or L116 mutant hCSPa were expressed in larval neurons with an elav-Gal4 driver from one (D–E, J–L) or two (A, H–I)
transgenes. Genotypes are indicated. (A) Larval NMJs immunostained for hCSPa, endogenous dCSP, and the neuronal membrane marker HRP. White
lines denote line scans shown in C. (B) Larval VNCs stained for hCSPa. (C) Plots of hCSPa and dCSP fluorescence from single line scans through
synaptic boutons (white lines in A). (D) Larval VNC segments stained for hCSPa (red) and lysine-linked-ubiquitin visualizing ubiquitinated proteins (Ubi-
protein). (E) Larval brain segments stained for hCSPa and dCSP. (F) Synaptic bouton of larval NMJ stained for hCSPa and Ubi-proteins. (G) Proximal
larval segmental nerves stained for hCSPa. (H–I) Average levels of hCSPa (H) and dCSP (I) at synaptic boutons of larval NMJs (N > 4). (J) Cumulative
area of abnormal hCSPa accumulations in larval brains (N  3). (K–L) Average number of accumulations immunopositive for both hCSPa and ubiquitin
(K), or only positive for ubiquitin (L) but not hCSPa (N  4). Scale bars: 5 mm (A), 20 mm (B, G), 15 mm (D), 10 mm (E), 5 mm (F). Graphs display
mean ± SEM. Statistical analysis used one-way ANOVA (H–L); *, p<0.05; **, p<0.01; ***, p<0.001.
DOI: https://doi.org/10.7554/eLife.46607.006
The following figure supplements are available for figure 4:
Figure supplement 1. hCSP-L115 and -L116 abnormally accumulate with endogenous dCSP and ubiquitinated proteins.
Figure 4 continued on next page
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somata and synaptic boutons of NMJs (Figure 4D,F, and Figure 4—figure supplement 1B). In com-
parison to larvae expressing WT hCSPa, the amount of hCSPa accumulations containing ubiquiti-
nated proteins was significantly increased in CLN4 mutants (p<0.001; Figure 4K). Hence, the
abnormal accumulations of CLN4 mutant hCSPa are either enriched in ubiquitinated hCSPa oligom-
ers and/or contain other ubiquitinated proteins that are potentially destined for protein
degradation.
The co-immunostainings against hCSPa and ubiquitinated proteins also revealed a substantial
increase in the levels of ubiquitinated proteins that was not associated with accumulations of CLN4
mutant hCSPa (Figure 4D and Figure 4—figure supplement 1B). Brains of control (w1118) and lar-
vae expressing WT hCSPa contained a similar amount of ubiquitinated protein foci that were nega-
tive for hCSPa (Figure 4L), indicating that expression of WT hCSPa exerts little to no effect on
protein ubiquitination. In comparison, the amount of ubiquitinated protein foci that were not associ-
ated with mutant hCSPa was significantly increased in brains expressing hCSPa-L115 or -L116
(p<0.03; Figure 4L). Hence, CLN4 mutant hCSPa may directly or indirectly affect a step of protein
homeostasis that that leads to excessive protein ubiquitination of unrelated proteins.
CLN4 mutations in fly and human CSP have similar effects
To validate the observed phenotypes of CLN4 mutant hCSPa and exclude that they are not an arti-
fact of expressing mutant human proteins in fly neurons, we expressed CLN4 mutant dCSP2 (dCSP2)
containing the mutations V117R and I118D, which are analogous to the mutations L115R and L116D
in hCSPa (Figure 1A). All fly transgenes were inserted at the same transgenic insertion site as the
human transgenes. Elav-driven neuronal expression of dCSP2, dCSP-V117, or -I118D from a single
transgene had no effect on viability during development at 23˚C (not shown) and 27˚C (p>0.4; Fig-
ure 4—figure supplement 2A). Adult lifespan at 27˚C was also normal (Figure 4—figure supple-
ment 2D). However, doubling gene expression levels severely reduced the viability of animals
expressing WT dCSP, dCSP-V117 or -I118D (Figure 4—figure supplement 2B). Notably, the few
adult WT dCSP and dCSP-V117 animals exhibited rough eyes, abnormally inflated wings, impaired
locomotion and died within a day (not shown). Adult flies expressing dCSP-I118 were never
observed.
Like for CLN4 mutant hCSPa, levels of monomeric lipidated dCSP-V117 and -I118 were reduced
in comparison to WT dCSP (Figure 4—figure supplement 2C). Similar to its human analog L115
(Figure 2A), V117 reduced levels of monomeric dCSP more severely (Figure 4—figure supplement
2C). In addition, both V117 and I118 triggered the formation of SDS-resistant, high-molecular weight
oligomers (Figure 4—figure supplement 2C), which were absent for WT dCSP2 expression.
Expressing dCSP2-V117 and -I118 in dcsp deletion mutants had similar effects (Figure 4—figure
supplement 2C). Hence, the pathological features of the dominant CLN4 mutations reducing levels
of lipidated CSP monomers and triggering protein oligomerization are conserved between fly and
human CSP.
To determine the subcellular localization of CLN4 mutant dCSP in fly neurons, we expressed nor-
mal and CLN4 mutant proteins from a single transgene in neurons of homozygous dcsp deletion null
mutants. Like for mutant hCSPa, levels of dCSP-V117 and -I118 were reduced at synaptic boutons of
larval NMJs and the neuropil of the larval VNC (Figure 4—figure supplement 2E–F). Mutant dCSPs
also accumulated abnormally in axons and neuronal somata of the larval brains (Figure 4—figure
supplement 2E).
CLN4 mutant hCSPa accumulates on prelysosomal endosomes
To further define the nature of the co-accumulations of CLN4 mutant hCSPa with ubiquitinated pro-
teins, we tested a number of organelle markers for a potential colocalization. Mutant hCSPa
Figure 4 continued
DOI: https://doi.org/10.7554/eLife.46607.007
Figure supplement 2. Effects of CLN4-analogous mutations in dCSP.
DOI: https://doi.org/10.7554/eLife.46607.008
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accumulations did not colocalize with the endoplasmic reticulum (ER), cis-, or trans-Golgi complexes
(Figure 5A), which excluded a major defect in ER or Golgi trafficking.
A large fraction of mutant hCSPa co-accumulated with hLAMP1-GFP (Figure 5B–C), which labels
a heterogeneous population of organelles ranging from pre-degradative endosomal species to deg-
radative lysosome (Cheng et al., 2018; Saftig and Klumperman, 2009; Yap et al., 2018). A similar
large fraction of mutant hCSPa co-accumulated with hepatocyte growth factor regulated tyrosine
kinase substrate (HRS, Figure 5C,E), which is a critical component of ‘endosomal sorting complexes
required for transport’ (ESCRT) mediating the transition from early to late endosomes (Raiborg and
Stenmark, 2009). Only a small fraction co-localized with coexpressed Rab5-GFP (not shown) or the
autophagosomal marker ATG8/LC3-GFP (Figure 5D). No co-localization was observed with lyso-
somal Spinster-GFP (Figure 5B; Rong et al., 2011; Sweeney and Davis, 2002) or the late endoso-
mal protein Rab7 (not shown; Guerra and Bucci, 2016).
Notably, endosomes accumulating mutant hCSPa did not co-localize with the co-expressed phos-
phatidylinositol 3-phosphate (PI3P) sensor FYVE-GFP (Figure 5B), even though HRS requires PI3P for
membrane association (Mayers et al., 2013; Raiborg et al., 2001a). Hence, this suggests that all
Figure 5. CLN4 mutant hCSPa accumulates on LAMP1- and HRS-positive endosomes. hCSP-L116 was expressed
in larval neurons with an elav-Gal4 driver from one transgene. As indicated, respective reporter transgenes were
co-expressed. (A) Neurons of larval VNCs co-immunostained for hCSPa and the ER marker GFP-KDEL, the cis-
Golgi marker GMAP, or the trans-Golgi marker Golgin 245. (B) Neurons co-immunostained for hCSPa (red) and
co-expressed hLAMP1-GFP, Spinster-GFP or the PI3P marker FYVE-GFP. (C) Fraction of organelle markers
colocalizing with hCSPa accumulations (mean ± SEM; n  65, N  4). (D–E) Segments of larval brains costained for
hCSPa and ATG8/LC3-GFP (D) or HRS (E). (F) Synaptic boutons at larval NMJs co-stained for hCSPa and HRS. (G)
Neuron co-immunostained for hCSPa and coexpressed GFP-nSyb. Scale bars: 10 mm (D–E), 5 mm (A–B, F–G).
DOI: https://doi.org/10.7554/eLife.46607.009
The following figure supplement is available for figure 5:
Figure supplement 1. RNAi-mediated KD of TSG101 causes accumulation of dCSP on HRS-positive endosomes.
DOI: https://doi.org/10.7554/eLife.46607.010
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PI3P binding sites may be occupied on the abnormal endosomes accumulating mutant hCSPa. Alter-
natively, PI3P may be absent from these endosomes, which would imply an abnormal retention of
HRS. Taken together, these data suggest that CLN4 mutant hCSPa accumulates on prelysosomal
endosomes that are inefficiently processed for lysosomal fusion.
Consistent with the colocalization of mutant hCSPa with ubiquitinated proteins at axon terminals
(Figure 4F), HRS also colocalized with mutant hCSPa at synaptic boutons of NMJs (Figure 5F). This
raised the possibility that hCSPa-positive endosomes may originate from synaptic terminals. Consis-
tently, hCSPa-positive accumulations co-localized with SV-associated Synaptobrevin-GFP (Syb-GFP;
Figure 5C,G) while a small subset co-localized with the synaptic plasma membrane protein Syntaxin
1A (not shown). The CSPa chaperone clients Dynamin and SNAP-25 (Sharma et al., 2011;
Zhang et al., 2012) did not co-localize with hCSPa-positive endosomes (not shown).
CLN4 mutations cause various ultrastructural endo-membrane
abnormalities in axons and neuronal somata
Since CLN4 mutant hCSPa abnormally accumulates on prelysosomal endosomes, we used electron
microscopy to detect potential ultrastructural defects in membrane trafficking. Expression of hCSPa-
L115 and -L116 induced highly abnormal membrane structures in neuronal somata, the neuropil of
the larval VNC, and axons of segmental nerves (Figure 6). The most prominent and frequent abnor-
mal structures were multilamellar ‘membrane whirls’ of various shapes and density that contain
highly electron-dense membranes (arrowheads, Figure 6A–B,C–D,F–G). Like endosomal hCSPa-pos-
itive accumulations detected by confocal microscopy, membrane whirls were most frequently
observed in the neuropil of the VNC and axons of segmental nerves (Figure 6C–D). To a lesser
degree, they were present in the cytoplasm of neuronal somata (Figure 6A–B,F–G) and occasionally
the nucleoplasm (not shown). Sporadically, whirls were found on opposite sides of plasma mem-
branes of neighboring cells (arrowhead, Figure 6B).
In addition to electron-dense membrane whirls, a number of secondary (residual) lysosomes
(Figure 6A,E) and abnormal autophagosome- and/or amphisome-like structures were present (white
arrowhead, Figure 6F–I). Interestingly, EM-dense membranes forming whirls may interact with auto-
phagosomes (arrow, Figure 6G). Notably, somewhat similar ‘membrane whirl’ and autophagosome-
like structures were observed in various ESCRT loss of function mutants including TSG101, Snf7/
CHMP4B, VPS4 and CHMP2B (Doyotte et al., 2005; Lee et al., 2007; Razi and Futter, 2006).
Next to abnormal membranes structures, homogenous electron-dense accumulations of unknown
nature were frequently present in cellular regions of CLN4 mutant larval brains (arrow, Figure 6B,H).
A limiting membrane was not detectable for these EM-dense accumulations, which are reminiscent
but not identical of granular osmophilic deposits (GRODs) seen in post-mortem human tissue of
CLN4 patients (Anderson et al., 2013; Burneo et al., 2003; Noskova´ et al., 2011; Virmani et al.,
2005). Since these structures were absent from the VNC neuropil and segmental nerves, they are
unlikely a correlate for the abnormal endosomal accumulations of mutant hCSPa in axons.
Finally, a number of neurons that contained abnormal membrane structures also exhibited a
severe fragmentation of the nuclear envelope and bloated Golgi cisternae (Figure 6B), which
together likely indicate a late stage of neuronal dysfunction and neurodegeneration (Nixon, 2006).
Loss of ESCRT function causes endosomal accumulations of
endogenous dCSP but no oligomerization
To verify that WT CSP is normally trafficked through the endo-lysosomal pathway, we impaired
ESCRT function by an RNAi-mediated knock down (KD) of tumor suppressor gene 101 (TSG101),
which is part of the ESCRT-I complex acting downstream of HRS and required for late endosome for-
mation (Doyotte et al., 2005; Razi and Futter, 2006). Neuronal KD of TSG101 caused a mislocaliza-
tion of endogenous dCSP, which accumulated on HRS-positive endosomes in the neuropil and
neuronal somata of the larval VNC (Figure 5—figure supplement 1A). Abnormal dCSP accumula-
tions were also present in central regions of synaptic boutons of larval NMJs (Figure 5—figure sup-
plement 1B). Hence, WT CSP is likely being degraded though the endo-lysosomal pathway. This
conclusion is consistent with the low amounts of lysosome-associated CSPa in human fibroblasts,
N2A cells, mouse neurons, and lysosome-enriched fractions (Benitez and Sands, 2017;
Chapel et al., 2013; Schro¨der et al., 2007; Tharkeshwar et al., 2017).
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Figure 6. CLN4 mutations cause abnormal endomembrane structures and EM-dense accumulations. TEM micrographs of ultrathin (70 nm) sections
from larval VNCs expressing hCSP-L115 or -L116 with an elav driver from two transgenic copies. Genotypes are indicated. (A–B) Neuronal somata
containing electron-dense membrane whirls (black arrowheads), large electron-dense extracellular deposits (black arrow, (B), and occasionally ‘residual
lysosomes’ (white arrow, (A), bloated Golgi Apparati (B), and degenerating nuclear membranes (white arrow, (B). (C) Neuropil of larval VNC containing
membrane whirls in neuronal processes (black arrowheads). (D) Sagittal section of larval segmental nerve containing membrane whirls and abnormal
autophagosome-like structures in axons of sensory and motor neurons. (E–H) High magnification images showing residual lysosome with a diverse
variety of intraluminal vesicles (E), various forms of EM-dense membrane whirls (F–G) and autophagosome-like structures (white arrowheads, (G–I) that
may interact with EM-dense structures (white arrow, (G), and an electron-dense extracellular deposit (H). Scale bars: 1 mm (A–C), 200 nm (D–E).
DOI: https://doi.org/10.7554/eLife.46607.011
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Notably, KD of TSG101 essentially mimicked the abnormal endosomal accumulation of CLN4
mutant hCSPa-L115 and -L116 with one important exception. In contrast to hCSPa-L115 and -L116
expression, KD of TSG101 did not cause the formation of high-molecular weight dCSP oligomers
(Figure 5—figure supplement 1C), indicating that CSP oligomer formation is independent of
impaired ESCRT function. In contrast to a recent report showing that impaired lysosomal activity in
mouse neurons decreases CSPa’s palmitoylation (Sambri et al., 2017), impaired prelysosomal
ESCRT function had no effect on the palmitoylation state of dCSP.
The CLN4 alleles hCSP-L115 and -L116 are hypermorphic gain of
function mutations
Several hypotheses regarding the genetic nature of the dominant CLN4 mutations have been sug-
gested. Mutant hCSPa monomers and/or oligomers could act as dominant-negatives that progres-
sively sequester WT hCSPa and deplete the functional hCSPa pool, which in turn could trigger
neurodegeneration (Greaves et al., 2012; Noskova´ et al., 2011; Zhang and Chandra, 2014). Alter-
natively, CLN4 mutant alleles may induce toxicity via a different gain of function (GOF) mechanism
(Greaves et al., 2012; Henderson et al., 2016; Zhang et al., 2012). Such a GOF mutation could
increase a normal activity of the protein (hypermorphic mutation) or introduce a new activity (neo-
morphic mutation). In theory, either type of mutation could trigger neurotoxicity.
To genetically address the genetic nature of CLN4 mutations, we examined to what degree alter-
ations of WT dCSP or hCSPa levels may affect L115 and L116 phenotypes. The rationale behind
these genetic experiments is simple: lowering WT levels should enhance dominant-negative pheno-
types, reduce hypermorphic phenotypes due to an increased normal activity, or have no effect on
neomorphic phenotypes due to a new protein activity (Muller, 1932; Wilkie, 1994).
Reducing endogenous WT dCSP levels by expressing two transgenic copies of CLN4 mutant
hCSP in heterozygous dcsp deletion mutants significantly suppressed the lethality induced by CLN4
mutations such that significantly more animals reached adulthood (p<0.02, Figure 7A). Conversely,
increasing levels of WT hCSPa by co-expressing WT hCSPa with either one copy of hCSP-L115 or -
L116 significantly reduced viability to ~54% and 48%, respectively (p<0.001, Figure 7B–C). The
lethality induced by co-expression of WT and CLN4 mutant hCSPa was significantly higher than the
lethality induced by two copy expression of WT hCSPa (p<0.03, Figure 7B–C). Hence, the modulat-
ing effects of altered WT dCSP or hCSPa levels on L115- and L116-induced lethality essentially
exclude the possibility that either mutation acts as a dominant-negative. Instead, these effects are
consistent with the genetic characteristics of a hypermorphic GOF mutation (Muller, 1932;
Wilkie, 1994).
Next, we determined whether altered WT CSP levels may modulate the tendency of CLN4 mutant
hCSPa to form abnormal high-molecular weight oligomers. Reducing WT dCSP levels by expressing
CLN4 mutant hCSPa in hetero- or homozygous dcsp deletion mutants significantly attenuated the
levels of SDS-resistant hCSP-L116 and -L115 oligomers (p<0.05; Figure 7D,F). Levels of hCSP-L116
and -L115 oligomers were attenuated to a similar degree (p>0.5; Figure 7F). Conversely, increasing
WT dCSP levels by co-expressing a WT transgene together with a single CLN4 mutant transgene
increased the amount of hCSP-L115 and L116 oligomers (p<0.007, Figure 7D,I). Coexpression of
WT hCSPa also significantly increased oligomerization of both hCSP-L116 and -L115 (p<0.008;
Figure 7E,L). In comparison, high-level overexpression of WT hCSPa from two transgenes did not
induce significant oligomerization (Figures 7E and 2A,C).
In contrast to the modulatory effects of WT CSP on mutant hCSPa oligomer levels, reducing or
even abolishing WT dCSP levels had no effect on the levels of lipidated monomeric hCSP-L115 and -
L116 (p>0.4; Figure 7G). Coexpressing WT dCSP2 or hCSPa with CLN4 mutant hCSPa increased
lipidated mutant hCSPa monomers (p<0.05; Figure 7J,M). Notably, coexpression of WT hCSPa
increased lipidated hCSP-L115 and -L116 monomers to levels that were similar to those of two copy
WT hCSPa expression (Figure 7M). This indicates that WT hCSPa may stabilize CLN4 mutant hCSPa
monomers.
Levels of non-lipidated monomeric CLN4 mutant hCSP were unaffected by reducing the gene
dosage of endogenous WT dCSP2 (p>0.3; Figure 7H). However, coexpression of either WT dCSP2
or hCSPa with CLN4 mutant hCSPa increased levels of non-lipidated mutant hCSPa monomers
(p<0.05; Figure 7K,N). At least the increase induced by WT hCSPa was non-additive since it was sig-
nificantly larger than the increase induced by doubling WT hCSPa expression (p<0.013; Figure 7N).
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Hence, increased levels of WT CSP may outcompete CLN4 mutant hCSPa for palmitoylation or,
alternatively, promote its depalmitoylation.
Finally, we tested whether altering levels of endogenous dCSP also affects other phenotypes of
the CLN4 fly model. Indeed, reducing dCSP levels by one gene copy significantly suppressed the
endosomal accumulation of both hCSP-L115 and -L116 in larval VNCs (p<0.05; Figure 8A–B). Reduc-
ing dCSP gene dosage also decreased the amount of accumulating ubiquitinated proteins in the
Figure 7. Altering wild type CSP levels modifies CLN4 phenotypes. WT hCSPa, hCSP-L115 or -L116 were expressed in neurons from one or two
transgenes (2x) with an elav driver in control (w1118), heterozygous cspX1/+, and homozygous cspX1/R1 deletion mutants, or co-expressed with WT hCSPa
or dCSP. Genotypes are indicated. (A–C) Effects of reducing endogenous dCSP (A) or co-expressing WT hCSPa (B–C) on the viability of hCSP-L115 and
-L116 mutant flies (N > 3; n > 144). (D–E) Immunoblots of protein extracts from larval VNC of indicated genotype probed for hCSPa and b-tubulin
(loading control). hCSPa oligomers (OM), lipidated (LM), non-lipidated hCSPa monomers (NLM), and unspecific signals (*) are denoted. (F–N) Effects of
reduced endogenous dCSP (F–H), increased dCSP (I–K), and increased WT hCSPa (L–N) levels on hCSPa oligomers (F, I, L), lipidated monomers (G, J,
M), and non-lipidated monomers (H, K, N). Signals were normalized to loading control and plotted as n-fold change of L115 or L116 levels when
expressed in a WT background (N = 5). Graphs display mean ± SEM. Statistical analysis used unpaired t test (A, I–L) or one-way ANOVA (B–C, F–H, M–
N); *, p<0.05; **, p<0.01; ***, p<0.001.
DOI: https://doi.org/10.7554/eLife.46607.012
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larval VNC (p<0.04; Figure 8C). However, reduced dCSP levels significantly enhanced the already
reduced synaptic protein levels of hCSP-L115 and -L116 at larval NMJs (p<0.03; Figure 8D). The
underlying cause for the latter effect is unclear.
Taken together, the modulating effects of altering WT fly and human CSP levels on L115- and
L116-induced phenotypes in viability, mutant hCSPa oligomerization, accumulation on endosomes
and ubiquitinated proteins suggest that the hCSP-L115 and -L116 alleles are hypermorphic gain of
function mutations that increase an intrinsic activity. This conclusion is consistent with a recent study
showing similar gene dosage effects of WT CSPa on hCSP-L115R phenotypes in mouse CSPa-defi-
cient fibroblasts (Benitez and Sands, 2017). In addition, these findings uncover a correlation
between the reduced viability of CLN4 mutant flies, the degree of mutant hCSPa oligomerization
and the failure of degrading oligomers.
Partial loss of CSPa’s chaperone partner Hsc70-4 suppresses CLN4-
induced phenotypes
The hypermorphic nature of CLN4 mutations raised the possibility that at least some of the induced
phenotypes are caused by an abnormally increased co-chaperone activity of CSP with the molecular
chaperone Hsc70, which normally ensures efficient SV exo- and endocytosis by likely chaperoning
SNARE proteins and Dynamin (Chandra et al., 2005; Nie et al., 1999; Sharma et al., 2012;
Sharma et al., 2011; Zhang et al., 2012). To address this possibility, we tested whether altered lev-
els of SNARE proteins or Hsc70 may modify the eye phenotypes induced by GMR-driven expression
of CLN4 mutant hCSPa (Figure 9A).
Reducing endogenous Hsc70-4 (Hsc4) levels by expressing hCSP-L116 in heterozygous hsc4D356
deletion mutants (Bronk et al., 2001) significantly suppressed both the structural and depigmenta-
tion defects of L116 mutant eyes (p=0.005; Figure 9A,E). Co-expression of a UAS hairpin transgene
knocking down Hsc4 also suppressed the L116 eye phenotype (p=0.007; Figure 9A,E). However,
reducing the gene dosage of Hsc70-3 or Hsc70-5 had no effect (not shown), indicating that the sup-
pression of L116-mutant eye phenotypes by reduced levels of Hsc4 is not a general effect of Hsc70
proteins. Co-expression of either Syntaxin 1A (Syx1A) or neuronal Synaptobrevin (nSyb) with hCSP-
L116 enhanced the L116 eye phenotype (p<0.01; Figure 9A,D). Overexpression or RNAi-mediated
knockdown of SNAP25 had no effect (not shown), even though a heterozygous deletion of SNAP25
enhanced degenerative phenotypes of hCSPa knockout mice (Sharma et al., 2012). Individual
Figure 8. Effects of reduced dCSP levels on CLN4 mutant hCSPa localization and protein ubiquitination. WT hCSPa, hCSP-L115 or -L116 were
expressed in neurons with an elav driver in control (w1118), heterozygous cspX1/+, or homozygous cspX1/R1 deletion mutants. (A) Larval VNC stained for
hCSPa and dCSP. Genotypes are indicated. Scale bar, 20 mm. (B–D) Effects of reduced dcsp gene dosage on the accumulation of hCSP-L115 and -L116
in larval VNC (B, N  3), ubiquitinated protein levels in larval VNCs (C, N  4), and synaptic levels of hCSP-L115 and -L116 at larval NMJs (D, N  4).
Signals were normalized and plotted as n-fold change to levels of elav-L115 and -L116 expression in WT control background. Graphs display
mean ± SEM. Statistical analysis used a paired (D) and unpaired t test (B–C); *, p<0.05; **, p<0.01; ***, p<0.001.
DOI: https://doi.org/10.7554/eLife.46607.013
Imler et al. eLife 2019;8:e46607. DOI: https://doi.org/10.7554/eLife.46607 15 of 34
Research article Neuroscience
overexpression of Syntaxin 1A (Syx1A), neuronal Synaptobrevin (nSyb), or SNAP25 had no effect on
the eye (not shown).
To further test whether Hsc4 may at least in part contribute to CLN4 phenotypes, we examined
effects of altered Hsc4 levels on the lethality induced by pan-neuronal expression of CLN4 mutant
hCSPa. Reducing the gene dosage of hsc4 by expressing mutant hCSP-L115 or L116 in
Figure 9. Reducing the gene dosage of Hsc4 attenuates CLN4 phenotypes. (A) Adult eyes of flies expressing WT hCSPa (control) or hCSP-L116 with a
GMR-Gal4 driver in the absence or presence of a heterozygous Hsc4+/- (hsc4D356) deletion, a Hsc4 KD (34836), OE of Syx1A or Syb. (B–D) Immunoblots
of extracts from larval VNCs of indicated genotypes were probed for hCSPa. Lipidated monomeric hCSP (LM), non-lipidated hCSP (NLM) and hCSPa
oligomers (OM) are indicated. Respective transgenes were expressed with an elav-driver; control was w1118. b-tubulin was used as loading control.( E)
Semi-quantitative assessments of genetic modifier effects on L116-induced eye phenotypes (N  12).( F) Viability of animals expressing hCSPa-L115 or -
L116 from two transgenes driven by elav-Gal4 in a control (w1118) or a heterozygous hsc4D356 deletion background (N  3; n > 74). (G-K) Effects of
reduced hsc4 gene dosage on levels of hCSPa oligomers (G), lipidated monomers (H), non-lipidated monomers (I) and total protein levels (J). Signals
were normalized to loading control and plotted as n-fold change to levels induced by elav-driven expression of hCSP-L115 or -L116 in a WT control
background (N > 6). (K) Effect of reduced hsc4 gene dosage on lipidated WT hCSPa monomer levels (N = 4). (L) Effects of reduced hsc4 gene dosage
on endosomal accumulations of hCSP-L115/L116 in larval VNC (N  4). (M–N) Effects of reduced hsc4 gene dosage on ubiquitinated protein levels in
larval VNCs (M, N = 5) and synaptic hCSP-L115/L116 expression levels at larval NMJs (N, N = 6). Signals were normalized and plotted as n-fold change
from levels of elav-L115/L116 expression in WT control background. (O) Motor neuron somata of larval VNCs co-expressing HA-tagged Hsc4 with
mutant hCSPa-L115 or -L116 stained for HA and hCSPa. Scale bars: 20 mm (K), 15 mm (M). Graphs display mean ± SEM. Statistical analysis used an
unpaired t test (F, M), paired t test (L, N), or one-way ANOVA (E, G–J); *, p<0.05; **, p<0.01; ***, p<0.001.
DOI: https://doi.org/10.7554/eLife.46607.014
The following figure supplement is available for figure 9:
Figure supplement 1. Effects of altered hsc4 gene dosage on CLN4 mutant hCSPa protein expression and localization.
DOI: https://doi.org/10.7554/eLife.46607.015
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heterozygous hsc4D356 deletion mutants significantly suppressed their lethality (p<0.0001;
Figure 9F). Hence, Hsc4 contributes to the toxicity of CLN4 mutations.
Next, we examined to what degree altered Hsc4 levels may attenuate the oligomerization of
CLN4 mutant hCSPa. Hsc4 OE had no significant effects on the amount of hCSP-L115 and -L116
oligomers, monomers and overall protein levels (p>0.05; Figure 9—figure supplement 1A–D).
However, reducing Hsc4 levels by expressing mutant hCSP-L115 or L116 in heterozygous hsc4D356
deletion mutants significantly reduced the amount of hCSP-L115 and -L116 oligomers (p<0.02;
Figure 9B–C,G) but had no differential effects (p>0.8). It also reduced the levels of lipidated and
non-lipidated hCSP-L115 and -L116 monomers, as well as overall protein levels (p<0.05; Figure 9H–
J). The overall reduction of CLN4 mutant hCSPa could have been due to a general dependence of
hCSPa expression on normal Hsc4 levels. However, this is unlikely the case since reducing Hsc4 lev-
els had no effect on the levels of monomeric WT hCSPa (Figure 9K), which was consistent with the
normal dCSP levels observed in hsc4 deletion mutants (Bronk et al., 2001).
Reducing Hsc4 levels also suppressed the amount of hCSP-L115 and -L116 protein accumulations
on endosomes in the larval VNC (p<0.05; Figure 9L and Figure 9—figure supplement 1E). It also
suppressed the amount of ubiquitinated protein accumulations induced by hCSP-L116 (p<0.05) but
had no effect on L115-induced levels (p=0.8; Figure 9M). Reducing hsc4 gene dosage had no effect
on the synaptic levels of hCSP-L116 at larval NMJs (p=0.7; Figure 9N). However, it further lowered
the synaptic levels of hCSP-L115 (p<0.01; Figure 9N). The underlying cause for these differential
effects is unclear.
In conclusion, the suppression effects of a reduced hsc4 gene dosage on the oligomerization and
abnormal accumulation of CLN4 mutant hCSPa on endosomes suggest that Hsc4 significantly con-
tributes to this pathology. Since HA-tagged Hsc4 colocalized with the abnormal accumulations of
hCSP-L115 and -L116 (Figure 9O), it may interfere with the prelysosomal trafficking and subsequent
degradation of mutant hCSPa. Consistently, lower Hsc4 levels reduced the overall protein levels of
mutant but not WT hCSPa (Figure 9J–K).
Discussion
To better understand pathological mechanisms underlying CLN4, we developed two Drosophila
models by expressing either CLN4 mutant hCSPa or dCSP in neurons. Neuronal expression of either
mutant hCSPa or dCSP mirrored key pathological features of post-mortem human CLN4 brains,
including reduced levels of palmitoylated hCSPa monomers and excessive formation of oligomers.
Consistent with the idea that ubiquitination is likely a consequence of oligomerization, only ubiquiti-
nated mutant hCSPa oligomers were detected but no ubiquitinated monomers. In general, the L115
mutation had stronger effects than L116, which has also been observed in post mortem brains and
mammalian cell cultures (Diez-Ardanuy et al., 2017; Greaves et al., 2012; Henderson et al., 2016;
Zhang and Chandra, 2014). Accordingly, expression of CLN4 mutant hCSPa or dCSP in fly neurons
provides a valid CLN4 disease model.
Dose-dependency of phenotypes in the Drosophila CLN4 model
To assess the dose-dependency of CLN4 phenotypes in the fly model, we controlled the gene dos-
age of transgenically expressed CLN4 mutant hCSPa by neuronally expressing either one or two
mutant transgenes in the presence of two endogenous WT dCSP gene copies.
Single copy expression of CLN4 mutant hCSPa did not cause detectable degeneration or lethal-
ity, even though significant levels of ubiquitinated hCSPa oligomers and abnormal prelysosomal
accumulations of hCSPa were present. However, doubling the gene dosage reduced the viability of
CLN4 mutant flies, which is likely due to neurodegeneration as indicated by fragmentated nuclear
envelopes and ‘bloated’ Golgi cisternae of larval neurons (Figure 6B). The significant drop in viability
indicated a sharp threshold of neurotoxicity, which was correlated with an increase in the levels of
hCSPa oligomers and prelysosomal accumulations. Consistent with a neuronal failure, adult escapers
showed reduced locomotor activity.
A similar dose-dependent effect was observed for the eye phenotype induced by GMR-driven
expression of CLN4 mutant hCSPa. The build-up of these pathological features in the CLN4 fly
model agrees with the assumed general concept of late onset neurodegenerative diseases, which
typically show a progressive accumulation of protein aggregates and defects in protein homeostasis
Imler et al. eLife 2019;8:e46607. DOI: https://doi.org/10.7554/eLife.46607 17 of 34
Research article Neuroscience
over a long period that is met by a declining age-dependent capacity of protein homeostasis
(Labbadia and Morimoto, 2015).
CLN4 mutations impair hCSPa’s synaptic localization
Previous studies speculated that CLN4 mutations may disrupt the trafficking and/or SV localization
of hCSPa (Benitez et al., 2011; Greaves et al., 2012; Noskova´ et al., 2011), mainly because
they reside in CSP’s palmitoylated CS domain. The CLN4 fly model confirms this prediction in two
ways: First, CLN4 mutations reduced the synaptic levels of mutant hCSPa. Second, they caused
abnormal accumulations of mutant hCSPa in axons and neuronal somata. Analogous CLN4 muta-
tions in fly dCSP had similar effects excluding the possibility that these defects are the consequence
of expressing a human protein in fly neurons.
In principle, there are two possibilities how CLN4 mutations may mislocalize CSP: 1) CLN4 muta-
tions may primarily impair palmitoylation of the CS domain, which is required for ER and Golgi exit,
and for a stable association with SVPs and/or SVs (Greaves and Chamberlain, 2006; Greaves et al.,
2008; Ohyama et al., 2007; Stowers and Isacoff, 2007). However, this possibility is unlikely the
case since mutant hCSPa was not detectable in the ER or Golgi of fly neurons. In addition, levels of
non-lipidated CLN4 mutant hCSPa were similar to WT hCSPa when expressed from one transgenic
copy. 2) CLN4 mutations may primarily induce oligomerization by exaggerating the dimerization
properties of the CS domain (Xu et al., 2010) such that self-association leads mostly to misfolded
high-molecular weight oligomers. Notably, oligomerization of CLN4 mutant hCSPa can be sup-
pressed by alanine or leucine substitutions of a cluster of palmitoylated cysteines (C122-125) located
next to the L115/116 mutations (Diez-Ardanuy et al., 2017), which is consistent with the idea that
CLN4 mutations primarily induce oligomerization.
In fly neurons, the oligomerization of mutant hCSPa is apparently triggered after exiting the
Golgi, either during its association with SVPs, or after arriving at axon terminals and associating with
SVs. The transition of SVP cargo onto SVs or endosomes is not well understood but in principle SVPs
can fuse with SVs, the synaptic plasma membrane, and endosomes (Rizzoli, 2014). In contrast, SVs
are linked to endosomes either by ultrafast endocytosis, or the ability of freshly endocytosed individ-
ual SVs to fuse with endosomes (Hoopmann et al., 2010; Soykan et al., 2017; Watanabe and Bou-
crot, 2017; Watanabe et al., 2013a; Watanabe et al., 2013b). Mutant hCSPa oligomers are
potentially re-routed from both SVPs and SVs because some mutant hCSPa colocalizes with SVs at
axon terminals. Nevertheless, re-routing of ubiquitinated oligomers is likely the main factor reducing
synaptic levels of CLN4 mutant hCSPa.
The ubiquitination of CLN4 mutant hCSPa oligomers likely indicates that they are misfolded and
thus targets for ubiquitination and degradation like other misfolded proteins (Wang et al., 2017).
Consistently, only ubiquitinated mutant hCSPa oligomers but no ubiquitinated monomers were
detected in fly neurons. Since WT dCSP (Figure 5—figure supplement 1) and hCSPa are mostly
degraded by lysosomes (Benitez and Sands, 2017; Chapel et al., 2013; Sambri et al., 2017;
Schro¨der et al., 2007; Tharkeshwar et al., 2017), one expects that ubiquitinated mutant hCSPa
oligomers are sorted into the endolysosomal pathway if they remain associated with membranes.
This appears to be the case since the majority of abnormal mutant hCSPa accumulations in fly neu-
rons represented prelysosomal endosomes, which were defined by the colocalization of ubiquiti-
nated proteins and the prelysosomal markers LAMP1-GFP and HRS. Finally, the suppression of
mutant hCSPa phenotypes by reduced dCSP or Hsc4 levels revealed a strong link between the olig-
omerization of mutant hCSPa, its re-routing onto prelysosomal membranes, and its induced lethality
(Figures 7–8). Hence, these data suggest that CLN4 mutations may primarily induce oligomerization
of membrane-associated hCSPa, which causes ubiquitination and re-routing into lysosomal
pathways.
CLN4 mutations impair prelysosomal trafficking of hCSPa
Axonal prelysosomal endosomes containing mutant hCSPa are likely retrogradely trafficked for lyso-
somal processing since degradative lysosomes containing cathepsin B/D are essentially absent from
distal axons (Cai et al., 2010; Cheng et al., 2018; Gowrishankar et al., 2015). Both the axonal traf-
ficking as well as the maturation of prelysosomal endosomes containing mutant hCSPa are poten-
tially impaired. A physical defect in axonal trafficking is indicated by the large size of the hCSPa
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accumulations and by the frequent occurrence of large and abnormal EM-dense membrane struc-
tures in axons of CLN4 mutants, which have the potential to ‘clog’ axons.
A reduced efficiency in the maturation of mutant hCSPa-positive prelysosomal endosomes is indi-
cated by their abnormally large size and by their failure to co-label with the PI3P lipid reporter FYVE-
GFP. The latter may be due to two alternatives: First, hCSPa-positive endosomes may have normal
PI3P levels but most of it is bound by PI3P-binding proteins. At least in part, this could be facilitated
by HRS (Raiborg et al., 2001a), which strongly co-labels with hCSPa accumulations. Alternatively,
PI3P could be depleted from these endosomal membranes, which then would imply that HRS is
abnormally retained.
Since only a small number of mutant hCSPa accumulations co-localized with the early endosome
marker Rab5 but essentially no accumulations colocalized with the late endosomal or lysosomal
markers Rab7 and spinster, it is possible that mutant hCSPa may impair the transition from early to
late endosomes.
The frequent occurrence of abnormal, multi-laminar structures containing EM-dense membranes
and abnormal autophagosome-like structures further indicate that CLN4 mutations impair steps of
membrane trafficking in axons and somata. Since similar ultrastructural defects were observed after
disruption of ESCRT function (Doyotte et al., 2005; Lee et al., 2007), the abnormal endosomal
membranes of CLN4 mutants suggest a defect in prelysosomal trafficking. This is further supported
by the accumulation of mutant hCSPa on prelysosomal membranes including ATG8/LC3-GFP posi-
tive autophagosomes. Alternatively, at least some of the abnormal membrane structures of CLN4
mutants could be the consequence of defects in the unconventional secretion of misfolded cytosolic
proteins, which is facilitated by CSP proteins at least in non-neuronal cells (Xu et al., 2018).
The CLN4 fly model also provides evidence for a general protein ubiquitination defect. Both of
the CLN4 mutations caused an increase in ubiquitinated protein accumulations in axons and neuro-
nal somata that were not associated with accumulations of CLN4 mutant hCSPa. Consistent with an
altered protein homeostasis, significant proteomic and lipidomic changes were found in CLN4
mutant post-mortem brains (Henderson et al., 2016). Even though CLN4 mutant CSPa’s ability to
stimulate the ATPase activity of Hsc70 progressively deteriorates in vitro (Zhang and Chandra,
2014), the excessive ubiquitination phenotype of the fly model is unlikely due to a reduced CSP/
Hsc70 chaperone function since reducing WT dCSP levels suppressed the ubiquitination effects.
Hence, the excessive ubiquitination may be a secondary consequence of the prelysosomal trafficking
defects induced by CLN4 mutations.
CLN4 alleles genetically resemble hypermorphic gain of function
mutations
Previously, it has been suggested that the progressive oligomerization of CLN4 mutant hCSPa may
cause a dominant-negative effect by sequestering and depleting WT CSPa (Greaves et al., 2012;
Henderson et al., 2016; Noskova´ et al., 2011; Zhang and Chandra, 2014). However, CLN4 mutant
hCSPa had no effect on the synaptic and overall levels of endogenous WT dCSP in the fly model. In
addition, decreasing or even abolishing WT dCSP reduced oligomer formation of mutant hCSPa.
Both effects are inconsistent with a dominant-negative effect of L115 and L116 mutations. In addi-
tion, genetic analysis of other phenotypes found no evidence supporting dominant-negative effects
in the CLN4 fly model. Instead, this analysis suggests that most of the observed phenotypes are due
to gain of function effects.
Reducing or abolishing WT dCSP levels suppressed the oligomerization and endosomal accumu-
lation of CLN4 mutant hCSPa, the elevated protein ubiquitination, and the premature lethality.
Increasing WT dCSP or hCSPa levels enhanced the oligomerization and lethality of CLN4 mutations.
Taken together, these results suggest that the respective phenotypes are due to a hypermorphic
gain of function mutation that increases an activity of hCSPa. A similar dependence of CLN4 pheno-
types on increased WT CSPa levels was observed in primary fibroblasts of CSPa-deficient mice after
co-expressing WT CSPa with CSPa-L115R, which increased levels of CSPa oligomers and lysosomal
lysotracker signals (Benitez and Sands, 2017).
Notably, there are also CLN4 phenotypes of the fly model that could not be genetically classified
in an unambiguous manner. These phenotypes include the effects of altered dCSP levels on mono-
meric and synaptic levels of CLN4 mutant hCSPa, which were either not affected or further reduced
by lower dCSP levels.
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The primary effect of the gain of function mutation induced by L115 and L116 is not known. How-
ever, the fly model revealed a correlation among the degree of mutant hCSPa oligomerization, accu-
mulation on endosomes, and lethality. Accordingly, it seems possible that CLN4 mutations primarily
drive the excessive oligomerization of hCSPa by exacerbating the known dimerization properties of
the CS domain (Xu et al., 2010). Such an effect would explain the excessive routing of the likely mis-
folded oligomers into prelysosomal pathways and the depletion of mutant hCSPa at synapses. The
impaired processing of the endosomes containing accumulating mutant hCSPa is then potentially a
secondary effect of misfolded oligomers.
Another possibility for the gain of function effect arises from the recently described role of hCSPs
on late endosomes for an unconventional secretion pathway, termed misfolding-associated protein
secretion (MAPS) (Xu et al., 2018). Even though it is unclear whether neuronal hCSPa participates in
MAPS, the gain of function effect could exacerbate the trafficking of hCSPa onto late endosomes
for MAPS after exiting the Golgi. Together, an excessive routing onto endosomes and oligomeriza-
tion of mutant hCSPa may then impair membrane trafficking pathways requiring late endosomes like
the lysosomal and MAPS pathways.
The dependence of key CLN4 phenotypes on WT CSP levels paralleled the modulatory effects of
hCSPa’s main interaction partner, Hsc70. Similar to reducing WT dCSP levels, reducing levels of
Hsc4 by one gene copy suppressed the lethality and eye phenotypes induced by CLN4 mutant
hCSPa, its oligomerization and endosomal accumulation. These modulatory effects are driven either
by an individual activity of Hsc70 itself, or by a synergistic activity of the CSP/Hsc70 complex. Nei-
ther of these activities are necessarily localized to SVs. In support of the latter, co-expressed HA-
tagged Hsc70-4 co-localized with the accumulations of CLN4 mutant hCSPa on endosomes, which
may interfere with the dissociation of clathrin coats that are anchored by the ESCRT component HRS
(Raiborg et al., 2001b). Alternatively, the respective Hsc70 activity may be associated with endoso-
mal microautophagy (Sahu et al., 2011; Uytterhoeven et al., 2015) or the unconventional secretion
of misfolded cytosolic proteins (Xu et al., 2018). At least for this fly model, an activity of Hsc70 asso-
ciated with chaperone-mediated autophagy (Kaushik and Cuervo, 2012) can be excluded since the
critical lysosomal translocator LAMP-2 is absent in flies (Uytterhoeven et al., 2015).
Concluding remarks
This initial study of the CLN4 fly model revealed a number of novel and important insights into the
pathology of CLN4, most notably, the unexpected genetic nature of CLN4 mutations, the mislocali-
zation of mutant hCSPa, a general ubiquitination defect, and prelysosomal processing defects. The
modulating effects of altered WT CSP or Hsc70 levels on key CLN4 phenotypes provided a strong
correlation between the premature lethality of CLN4 mutant flies, oligomerization and accumulation
of mutant hCSPa on prelysosomal endosomes. Accordingly, the neurotoxicity of CLN4 mutant
hCSPa may be at least in part due to the formation of ubiquitinated hCSPa oligomers that then pro-
gressively accumulate on prelysosomal endosomes and interfere with their processing for lysosomal
fusion and potentially their retrograde axonal trafficking.
The pathological mechanisms underlying CLN4 appear to be different from those of most other
NCLs, which are typically due to loss of function mutations in genes that mediate lysosomal function,
ER-lysosomal trafficking, or protein lipidation (Ca´rcel-Trullols et al., 2015; Cooper et al., 2015;
Cotman et al., 2013; Mole and Cotman, 2015; Warrier et al., 2013). As such, the pathological
mechanisms underlying CLN4 appear similar to those of ‘classical’ neurodegenerative diseases that
are induced by a progressive build-up of protein oligomers/aggregates that then leads to a failure
of protein homeostasis and/or lysosomal pathways (Abramov et al., 2009; Labbadia and Mori-
moto, 2015; Lansbury and Lashuel, 2006; Muchowski and Wacker, 2005; Neefjes and van der
Kant, 2014). While we are just beginning to understand the complicated nature of CLN4, the fly
model provides a valuable tool for future work to dissect pathological mechanisms underlying CLN4.
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Materials and methods
Key resources table
Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Gene (Drosophila
melanogaster)
csp Flybase FLYB:FBgn0004179 Cysteine
string protein
Gene (human) DNAJC5 NCBI GeneID:80331 Encodes CSPa
Transcript
(Drosophila
melanogaster)
dCSP-2/CSP-PC NCBI Genbank NM_168950.4 Reference Sequence
used for synthesis of
dCSP constructs,
ORF: 186–872
Recombinant
DNA reagent
pBID-UASC Wang et al., 2012 RRID:Addgene_35200 PhiC31 attB 10xUAS
vector for site specific
recombinase
insertions
Recombinant
DNA reagent
pUC57-dCSP2.WT Genscript; This paper Full length wildtype
dCSP2
ORF with Kozak
sequence and
NotI/KpnI
restrictions sites
cloned into pUC57
Recombinant
DNA reagent
pUC57-dCSP2.V117R Genscript; This paper As above with V117R
mutation
Recombinant
DNA reagent
pUC57-dCSP2.I118D Genscript; This paper As above with I118D
mutation
Recombinant
DNA reagent
PGEX-KG_rCSPa Zhang and Chandra, 2014 Wildtype rat CSPa cDNA
sequence with
V112F point
mutation to match
human aa sequence
Recombinant
DNA reagent
PGEX-KG_
hCSPa.L115R
Zhang and Chandra, 2014 As above with L115R
mutation
Recombinant
DNA reagent
PGEX-KG_
hCSPa.L116D
Zhang and Chandra, 2014 As above with L116D
mutation
Recombinant
DNA reagent
pBID-UASC_
CSPa.WT
This study full length wildtype ORF
encoding
rat/human CSPa
cloned into pBID-UASC
transformation vector
Recombinant
DNA reagent
pBID-UASC_
CSPa.L115R
This study As above with L115R
mutation
Recombinant
DNA reagent
pBID-UASC_
CSPa.L116D
This study As above with L116D
mutation
Recombinant
DNA reagent
pBID-UASC_
dCSP2.WT
This study Full length
wildtype ORF
encoding dCSP2
cloned into
pBID-UASC
transformation
vector
Recombinant
DNA reagent
pBID-UASC_
dCSP2.V117R
This study As above with V117R
mutation
Recombinant
DNA reagent
pBID-UASC_
dCSP2.I118D
This study As above with I118D
mutation
Sequenced-
based reagent
rCSP NotI for Sigma 5’-GAGCGGCC
GCCAAAATG
GCTGACCAGAGG
CAGCGCTC-3’
Continued on next page
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Continued
Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Sequenced-
based reagent
rCSP KpnI rev Sigma 5’-CATGGTACCT
TAGTTGA
ACCCGTCGGTGT
GATAGCTGG-3’
Genetic reagent
(D. melanogaster)
w[1118] Caltech collection:
Seymour Benzer,
Caltech
FlyB:FBal0018186 Genotype: w[1118];
isogenized genetic
background
Genetic reagent
(D. melanogaster)
elav::Gal4[C155] Bloomington
Drosophila Stock
Center
FlyB:FBst0000458;
RRID:BDSC_458
Genotype:
P{w[+mW.hs]=GawB}
elav[C155]
Genetic reagent
(D. melanogaster)
nSyb::Gal4 Hugo Bellen,
Baylor College
of Medicine
FlyB:FBst0051635;
RRID:BDSC_51635
Genotype: y[1] w[*];
P{w[+m*]=nSyb-GAL4.S}3
Genetic reagent
(D. melanogaster)
GMR::Gal4 Bloomington
Drosophila Stock
Center
FlyB:FBst0001104;
RRID:BDSC_1104
Genotype: w[*];
P{w[+mC]=GAL4 ninaE.
GMR}12
Genetic reagent
(D. melanogaster)
UAS::nsyb-EGFP Bloomington
Drosophila Stock
Center
FlyB:FBst0006921;
RRID:BDSC_6921
Genotype: w[*];
P{w[+mC]=UAS nSyb.
eGFP}2
Genetic reagent
(D. melanogaster)
UAS::GFP-myc-2xFYVE Bloomington
Drosophila Stock
Center
FlyB:FBst0042712;
RRID:BDSC_42712
Genotype: w[*];
P{w[+mC]=UAS-
GFP-myc-2xFYVE}2
Genetic reagent
(D. melanogaster)
UAS::TSG101 RNAi Bloomington
Drosophila Stock
Center
FlyB:FBst0035710;
RRID:BDSC_35710
Genotype: y[1] sc[*]
v[1] sev[21];
P{y[+t7.7] v[+t1.8]=TRiP.
GLV21075}attP2
Genetic reagent
(D. melanogaster)
UAS:GFP-KDEL Bloomington
Drosophila Stock
Center
FlyB:FBst0009898;
RRID:BDSC_9898
Genotype: w[*];
P{w[+mC]=UAS GFP.
KDEL}11.1
Genetic reagent
(D. melanogaster)
UAS::hLAMP1-GFP Bloomington
Drosophila Stock
Center
FlyB:FBti0150347;
RRID:BDSC_42714
Genotype: w[*];
P{w[+mC]=UAS-
GFP-LAMP}2;
P{w[+m*]=nSyb-GAL4.S}3/
T(2;3)TSTL,
CyO: TM6B, Tb[1]
Genetic reagent
(D. melanogaster)
UAS::GFP-Rab5 Bloomington
Drosophila Stock
Center
FlyB:FBst0043336;
RRID:BDSC_43336
Genotype: w[*];
P{w[+mC]=UAS-
GFP-Rab5}3
Genetic reagent
(D. melanogaster)
UAS::spin-myc.EGFP Bloomington
Drosophila Stock
Center
FlyB:FBst0039668;
RRID:BDSC_39668
Genotype: w[*];
P{w[+mC]=UAS spin.
myc-EGFP}B
Genetic reagent
(D. melanogaster)
UAS::GFP-LC3(ATG8) Bloomington
Drosophila Stock
Center
FlyB:FBst0008730;
RRID:BDSC_8730
Genotype: w[*];
P{w[+mC]=UASp-
eGFP-huLC3}1;
P{w[+mC]=GAL4::
VP16-nos.
UTR}CG6325[MVD1]
Genetic reagent
(D. melanogaster)
UAS::syx-1A Bloomington
Drosophila Stock
Center
FlyB:FBst0051619;
RRID:BDSC_51619
Genotype:
y[1] w[*];
P{w[+mC]=UAS-
Syx1A.B}6
Genetic reagent
(D. melanogaster)
UAS::hsc70-4 KD1 Bloomington
Drosophila Stock
Center
FlyB:FBst0054810;
RRID:BDSC_54810
Genotype: y[1] v[1];
P{y[+t7.7]
v[+t1.8]=TRiP.
HMJ21529}attP40
Continued on next page
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Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Genetic reagent
(D. melanogaster)
UAS::hsc70-4 KD2 Bloomington
Drosophila Stock
Center
FlyB:FBst0028709;
RRID:BDSC_28709
Genotype: y[1] v[1];
P{y[+t7.7]
v[+t1.8]=TRiP.
JF03136}attP2
Genetic reagent
(D. melanogaster)
UAS::hsc70-4 KD3 Bloomington
Drosophila Stock
Center
FlyB:FBst0034836;
RRID:BDSC_34836
Genotype: y[1] sc[*] v[1];
P{y[+t7.7] v[+t1.8]=TRiP.
HMS00152}
attP2/TM3, Sb[1]
Genetic reagent
(D. melanogaster)
attP-22A Bloomington
Drosophila Stock
Center
FlyB:FBst0024481;
RRID:BDSC_24481
Genotype: y[1] M
{vas-int.Dm}
ZH-2A w[*]; M
{3xP3-RFP.attP’}
ZH-22A PhiC31 Insertion
background,
all generated
lines outcrossed
into w[1118]
Genetic reagent
(D. melanogaster)
UAS::venus-Rab7.WT R Hisinger (Freie
Universita¨t, Berlin,
Germany);
Cherry et al., 2013
FlyB:FBal0294208
Genetic reagent
(D. melanogaster)
hsc70-4[D356] Bronk et al., 2001 FlyB:FBal0124174 Genotype: w[1118];;
hsc70-4[D356]
Genetic reagent
(D. melanogaster)
UAS::Hsc70-4 Karen Palter,
Temple University;
Elefant and Palter, 1999,
FlyB:FBst0005846;
RRID:BDSC_5846
Genotype: w[126];
P{w[+mC]=UAS-
Hsc70-4.WT}B
Genetic reagent
(D. melanogaster)
UAS:HA-Hsc70-4.WT P Verstreken;
Uytterhoeven
et al., 2015
FlyB:FBal0318413 Genotype: w[1118];
P{w[+mC]=UAS-
Hsc70-4.HA}
Genetic reagent
(D. melanogaster)
UAS::SNAP25 Bloomington
Drosophila Stock
Center
FlyB:FBst0051997;
RRID:BDSC_51997
Genotype: y[1] w[*];
P{w[+mC]=UAS-
Snap25.L}9
Genetic reagent
(D. melanogaster)
UAS::SNAP25 KD Bloomington
Drosophila Stock
Center
FlyB:FBst0027306;
RRID:BDSC_27306
Genotype: y[1] v[1];
P{y[+t7.7] v[+t1.8]=TRiP.
JF02615}attP2
Genetic reagent
(D. melanogaster)
csp[R1] Zinsmaier et al., 1994 FlyB:FBst0032035;
RRID:BDSC_32035
Genotype: w[1118];
csp[X1]/TM6Tb[1]Sb[1];
partial deletion of csp
(genetic null)
Genetic reagent
(D. melanogaster)
csp[X1] Zinsmaier et al., 1994 FlyB:FBst0051998;
RRID:BDSC_51998;
Genotype: w[1118];
csp[R1]/TM6Tb[1]Sb[1];
complete deletion of csp
locus, maintained
in this lab
Genetic reagent
(D. melanogaster)
UAS::dCSP2 this study Genotype: w[1118];
M{UAS-dCSP2}ZH-22A
Genetic reagent
(D. melanogaster)
UAS::dCSP2.V117R this study Genotype: w[1118];
M{UAS-dCSP2.V117R}
ZH-22A
Genetic reagent
(D. melanogaster)
UAS::dCSP2.I118D this study Genotype: w[1118];
M{UAS-dCSP2.I118D}
ZH-22A
Genetic reagent
(D. melanogaster)
UAS::hCSPa this study Genotype: w[1118];
M{UAS-hCSPa}ZH-22A
Genetic reagent
(D. melanogaster)
UAS::hCSPa.L115R this study Genotype: w[1118];
M{UAS-hCSPa.L115R}
ZH-22A
Continued on next page
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Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Genetic reagent
(D. melanogaster)
UAS::hCSPa.L116D this study v: w[1118];
M{UAS-hCSPa.
L116R}ZH-22A
Antibody anti-CSPa
(rabbit polyclonal)
Enzo Life Sciences Cat#: VAP-SV003E;
RRID:AB_2095057
Immunostaining
(IS, 1:2000);
Western Blot
(WB, 1:20000);
IP (1:250)
Antibody anti-dCSP
(mouse monoclonal)
Zinsmaier et al., 1990 Cat# DSHB:DCSP-1
(ab49);
RRID:AB_2307345
IS (1:20);
WB (1:250)
Antibody anti-GFP
(mouse monoclonal)
Developmental
Studies Hybridoma
Bank
Cat# DSHB:
GFP-12A6;
RRID:AB_2617417
IS (1:1000)
Antibody anti-HRS (guinea-
pig polyclonal)
HJ Bellen, Baylor
College of Medicine,
Houston, TX;
Lloyd et al., 2002
IS (1:2000);
WB (1:2000)
Antibody anti-HA
(rat monoclonal)
Roche Cat#: 3F10;
RRID:AB_2314622
IS (1:200)
Antibody anti-GM130
(rabbit polyconal)
Abcam Cat# ab31561,
RRID:AB_2115328
IS (1:200)
Antibody anti-Golgin245
(goat polyclonal)
Developmental
Studies Hybridoma
Bank
Cat#: Golgin245;
RRID:AB_2618260
IS (1:2000)
Antibody anti-GMAP
(goat polyclonal)
Developmental
Studies Hybridoma
Bank
Cat#: GMAP;
RRID:AB_2618259
IS (1:2000)
Antibody anti-Rab7
(mouse monoclonal)
Developmental
Studies Hybridoma
Bank
Cat#: Rab7;
RRID:AB_2722471
IS (1:100)
Antibody anti-Syx1A
(mouse monoclonal)
Developmental
Studies Hybridoma
Bank
Cat#: 8C3;
RRID:AB_528484
IS (1:200)
Antibody anti-b-tubulin
(mouse monoclonal)
Developmental
Studies Hybridoma
Bank
Cat#: E7;
RRID:AB_528499
WB (1:1000)
Antibody anti-conjugated-
ubiquitin
(mouse monoclonal)
Enzo Life Sciences Cat#: BML-PW8810;
RRID:AB_10541840;
Clone FK2
IS (1:2000); WB
(1:2000)
Antibody anti-HRP Alexa Fluor
647-conjugated
(goat polyclonal)
Jackson Immuno
Research Labs
Cat#: 123-605-021;
RRID:AB_2338967
IS (1:500)
Antibody anti-mouse IgG1
AlexaFluor
488-conjugated
(goat polyclonal)
Thermo Fisher
Scientific
Cat#: A-21121;
RRID:AB_2535764
IS (1:500)
Antibody anti-rabbit IgG (H+L)
Cy3-conjugated
(donkey polyclonal)
Jackson Immuno
Research Labs
Cat#: 711-165-152;
RRID:AB_2307443
IS (1:500)
Antibody anti-guinea pig IgG
(H+L) Alexa Fluor
488-conjugated
(goat polyclonal)
Thermo Fisher
Scientific
Cat#: A-1107;
RRID:AB_2534117
IS (1:1000)
Continued on next page
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Continued
Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Antibody anti-rat IgG (H+L)
Alexa Fluor
488-conjugated
(goat polyclonal)
Jackson Immuno
Research Labs
Cat#: 112-545-167;
RRID:AB_2338362
IS (1:500)
Antibody anti-rabbit IgG
(H+L) HRP-conjugated
(goat polyclonal)
Thermo Fisher
Scientific
Cat#: A16096;
RRID:AB_2534770
WB (1:10000)
Antibody anti-mouse IgG
HRP-conjugated
(goat polyclonal)
Thermo Fisher
Scientific
Cat#: 32430;
RRID:AB_1185566
WB (1:5000)
Commercial
assay or kit
Western
Clarity ECL kit
BioRad Cat#: 1705061
Commercial
assay or kit
A/G PLUS-
Agarose Beads
Santa Cruz
Biotechnology
Cat#: sc-2003
Software,
algorithm
FIJI/ImageJ NIH RRID:SCR_002285
Software,
algorithm
Prism Graphpad RRID:SCR_002798
Software,
algorithm
Adobe
Photoshop CC
Adobe RRID:SCR_014199
Software,
algorithm
Quantity One 1-D
Analysis Software
BioRad RRID:SCR_014280
Drosophila strains and husbandry
All flies were raised at 23˚C on standard cornmeal culture media with a 12/12 light-dark cycle unless
otherwise specified. Gal4 driver strains nSyb-Gal4, elav-Gal4(C155) and GMR-Gal4, and UAS strains
expressing EGFP-nSyb, GFP-myc-2xFYVE, TSG101 KD, hLAMP1-GFP, Spin-myc-EGFP, GFP-LC3
(ATG8), GFP-KDEL, nSyb-EGFP, Rab5-YFP, Rab7-YFP, Hsc70-4 KD (1-3), Syx1A, SNAP25, and
SNAP25 KD were obtained from the Bloomington Drosophila Stock Center (BDSC, Bloomington,
Indiana). UAS strains expressing Venus-Rab7 (Cherry et al., 2013), Hsc70-4 (Elefant and Palter,
1999), and HA-Hsc70-4 (Uytterhoeven et al., 2015) were obtained from P.R. Hiesinger (Freie Uni-
versita¨t, Berlin, Germany), K. Palter (Temple University, Philadelphia, PA) or P. Verstreken (VIB Cen-
ter for the Biology of Disease, Leuven, Belgium), respectively. The csp (R1, X1) and hsc70-4 (D356)
gene deletion alleles were generated previously by us (Bronk et al., 2001; Zinsmaier et al., 1994).
Generation of UAS transgenes
To generate transgenes that individually express human WT, L115R- and L116D-mutant CSPa under
the transcriptional control of the Gal4/UAS system (Brand and Perrimon, 1993), the open reading
frames of modified rat cDNAs encoding human WT and mutant CSPa (Zhang and Chandra, 2014)
were PCR amplified using a forward primer containing a NotI restriction site and a Drosophila con-
sensus Kozak sequence (5’ GAGCGGCCGCCAAAATGGCTGACCAGAGGCAGCGCTC 3’) and a
reverse primer containing a KpnI site just after the stop codon (5’ CATGGTACCTTAGTTGAACCCG
TCGGTGT GATAGCTGG 3’). The obtained PCR products were cleaved with NotI and KpnI and
directionally cloned into a NotI/KpnI cleaved pBID-UASC vector (Wang et al., 2012). cDNAs encod-
ing WT and CLN4 mutant dCSP were synthesized de novo (GenScript, Piscataway, NJ) using cDNA
sequences encoding the open reading frame of CSP2 (CSP-PC, accessionID: NM_168950.4)) as tem-
plate (Nie et al., 1999). The mutations V117R and I118D were introduced into dCSP2 to generate
CLN4 mutant dCSP. Both V117R and I118D are analogous to the human CLN4 mutations L115R and
L116D, respectively. The synthesized cDNAs contained a NotI site followed by a Kozak sequence at
the 5’ end and a Kpn1 site after the stop codon at the 3’ end and were inserted into pUC57 plas-
mids. For transgene expression, the cDNAs were then directionally subcloned into a pBID-UASC
vector using the NotI and KpnI cleavage sites.
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Transgenic animals were generated by fC31-based integration (Bischof et al., 2007) of the UAS
transgenes into the attP site at 22A2 on chromosome 2 (2L:1476459..1476459). pBID-UASC-CSP-x
plasmids were injected into y1 M[vas-int.Dm]ZH-22A w*; M[3xP3-RFP.attP’]ZH-22A (BDSC #24481)
embryos (Rainbow Transgenic Flies, Camarillo, CA). At least two independent recombinant strains
were obtained for each transgene and out-crossed to exchange non-recombinant chromosomes.
The 3xP3-RFP cassette was removed by loxP-mediated recombination as described (Bischof et al.,
2007). Homozygous strains containing UAS transgenes were established in a genetic background
representing WT control (w1118) and dcsp deletion mutants (w1118; dcspX1).
Crosses for single copy transgene expression were made by crossing homozygous male w1118,
elav-Gal4[C155] flies to homozygous w1118; M[UAS::CSP-x.]ZH-22A female flies yielding female F1
progeny expressing CSP-x (w1118, elav-Gal4[C155]/w1118; M[UAS::CSP-x]ZH-22A /+) and male prog-
eny containing a silent (non-expressed) transgene (w1118; M[UAS::CSP-x]ZH-22A/+). Crosses for two
copy expression were made by crossing females w1118, elav-Gal4[C155]; M[UAS::CSP-x]ZH-22A/
CyO, Actin-GFP to male w1118; M[UAS::CSP-x]ZH-22A. Female F1 progeny heterozygous for the elav
driver and homozygous for the UAS transgene (w1118, elav-Gal4[C155]/w1118; M[UAS::CSP-x}ZH-
22A) were selected for analysis.
dCSP null rescue
All genetic rescue experiments employing a csp-/- deletion null genetic background expressed WT
or CLN4 mutant hCSPa from a single transgene. Female w1118, elav-Gal4[C155]; cspR1/TM6 Tb Sb
flies were crossed to w1118; M[UAS::hCSP-x]ZH-22A; cspX1/TM6 Tb Sb males or w1118; cspX1/TM6 Tb
Sb males for control. Flies were raised at 23˚C. Male progeny (w1118, elav-Gal4[C155]; M[UAS::hCSP]
ZH-22A/+; cspX1/R1) were used because of higher expression and better rescue. 10–15 freshly
enclosed flies of the respective genotypes were cultured in separate vials and transferred weekly to
fresh food. Dead flies were scored daily.
Viability and adult lifespan
The following crossing scheme was used: For single copy expression, hemizygous w1118, elav-Gal4
[C155] males were crossed to homozygous w1118; UAS::CSP-x females yielding non-expressing F1
control males (w1118; UAS::CSP-x/+) and CSP-expressing F1 females (w1118, elav-Gal4[C155]/w1118;
UAS::CSP-x/+). For two copy expression, hemizygous w1118, elav-Gal4[C155]; UAS::CSP-x/CyO,
Actin-GFP males were crossed to homozygous w1118; UAS::CSP-x females yielding non-expressing
F1 males (w1118; UAS::CSP-x) and CSP-expressing F1 females (w1118, elav-Gal4[C155]/w1118; UAS::
CSP). Flies were raised at 23˚C or 28˚C. Viability was determined by scoring the ratio of freshly
enclosed females and male flies. Adult lifespan was determined by culturing freshly enclosed males
and females in separate vials and scoring dead flies daily or every 2nd day. Adult flies were trans-
ferred weekly to fresh food.
Immunostainings
Wandering 3rd instar larvae were dissected in Sylgard-coated dishes containing cold Ca2+ free HL3
solution (in mM: 70 NaCl, 5 KCl, 20 MgCl2, 10 NaHCO3, 5 Trehalose, 115 sucrose, 5 HEPES, pH 7.2).
Dissected larvae were fixed for 20 (VNC) or 45 min (NMJs) in 4% formaldehyde solution (Electron
Microscopy Sciences, Hatfield, PA) in phosphate-buffered saline (PBS), pH 7.3 at room temperature
(RT). PBS (pH 7.3) supplemented with 0.2% Triton X-100 (PBST) was used for immunostainings of lar-
val NMJs while PBS (pH 7.3) supplemented with 0.4% Triton X-100 was used for immunostainings of
larval VNCs. After washing 3 times for 10 min in PBST at RT, larvae were incubated with primary anti-
bodies diluted in PBST overnight at 4˚C, washed 3x for 15 min at RT, incubated with secondary anti-
bodies diluted in PBST for 2 hr at RT or overnight at 4˚C and finally washed 3x with PBST for 15 min
at RT. Confocal images were acquired the same day, otherwise preparations were post-fixed.
The following antibodies and dilutions were used: rabbit anti-CSPa, 1:2000 (Enzo Life Sciences
Cat# VAP-SV003E, RRID:AB_2095057); mouse anti-dCSP, 1:250 (DSHB Cat# DCSP-1 (ab49), RRID:
AB_2307345; Zinsmaier et al., 1990); mouse anti-GFP, 1:1000 (DSHB Cat# DSHB-GFP-12A6, RRID:
AB_2617417); guinea pig anti-HRS, 1:2000; (Lloyd et al., 2002), H. Bellen, Baylor College of Medi-
cine, Houston, TX); rat anti-HA, 1:200 (Roche Cat# 3F10, RRID:AB_2314622); rabbit anti-GM130,
1:200 (Abcam Cat# ab31561, RRID:AB_2115328); goat anti-Golgin245, 1:2000 (DSHB Cat#
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Golgin245, RRID:AB_2618260), goat anti-GMAP, 1:2000 (DSHB Cat# GMAP, RRID:AB_2618259);
mouse anti Rab7, 1:100 (DSHB Cat# Rab7, RRID:AB_2722471; Riedel et al., 2016); mouse anti-
Syx1A, 1:200 (DSHB Cat# 8c3, RRID:AB_528484); mouse anti-ubiquitin-conjugated protein, 1:2000
(Enzo Life Sciences Cat# BML-PW8810, RRID:AB_10541840); goat anti-HRP Alexa Fluor 647-conju-
gated, 1:500 (Jackson ImmunoResearch Labs Cat# 123-605-021, RRID:AB_2338967); goat anti-
mouse IgG1 Alexa Fluor 488-conjugated, 1:500 (Thermo Fisher Scientific Cat# A-21121, RRID:AB_
2535764); donkey anti-rabbit IgG (H+L) Cy3-conjugated, 1:500 (Jackson ImmunoResearch Labs Cat#
711-165-152, RRID:AB_2307443); goat anti-guinea pig IgG (H+L) Alexa Fluor 488-conjugated,
1:1000 (Thermo Fisher Scientific Cat# A-11073, RRID:AB_2534117); goat anti-rat IgG (H+L) Alexa
Fluor 488-conjugated, 1:500 (Jackson ImmunoResearch Labs Cat# 112-545-167, RRID:AB_2338362).
Confocal imaging
Stained preparations were imaged with an Olympus microscope BX50WI equipped with a confocal
laser scanner (FluoView 300), a 60X water-immersion objective (LUMPLFL; N.A., 0.9), a multi-argon
(630), a green HeNe (430), and a red HeNe (630) laser. Optical sections in the vertical axis were
acquired using 0.8 mm (NMJs) or 1.5 mm (VNC) intervals for optical sectioning using Fluoview soft-
ware. Images were analyzed offline using ImageJ software (FIJI v1.50, NIH).
For quantification of fluorescence signals, control and mutant larvae were dissected in the same
dish such that fixation and antibody incubation were performed identically. All samples were imaged
with the same laser settings. Fluorescence intensity per area was determined from a region of inter-
est (ROI) encompassing single synaptic boutons by using Image J Software.
For quantification of CSP accumulations in VNC, z-projections with maximal intensity of optical
sections were generated and cropped to a defined volume of 60  80  45 mm (216,000 mm3).
These image stacks represented the dorsal-most part of hemi-segments A4 and A5. After threshold-
ing for background subtraction, ROIs were drawn around all visible CSP-positive punctae; for those
appearing in multiple optical sections only the section with the brightest signal was used. ROI areas
were compiled to compare the cumulative area among genotypes.
Western blot analysis
Larval brains were dissected from wandering 3rd instar larvae in in phosphate-buffered saline (PBS,
pH 7.3) and five brains transferred to 60 mL buffer (2% SDS, 10% Glycerol, 60 mM Tris pH 6.8,
0.005% Bromophenol Blue, and 100 mM DTT). Brains were homogenized with a p200 pipette tip,
boiled for 5 min and centrifuged for 3 min at 2000 g. The soluble fraction was transferred to a fresh
tube, boiled for 1 min and an equivalent of ~1.5 brains was immediately loaded onto a 10% acrylam-
ide gel for SDS-PAGE at 80V (Mini-Protean Cell, BioRad, Hercules, CA). Separated proteins were
blotted onto nitrocellulose membranes at 20 V for 6 min using an iBlot system (Invitrogen, Carlsbad,
CA). After transfer, the blot was blocked for 30 min using 1% bovine serum albumin fraction V
(#BP1600-100, Fisher Scientific) in PBS supplemented with 0.2% Tween-20, pH 7.3 (PBSTw). Blots
were incubated with primary antibodies overnight at 4˚C, washed, and incubated with HRP-conju-
gated secondary antibodies for 2 hr at 4˚C. To normalize for protein loading, blots were stripped
(#21059; ThermoFisher Scientific) for 15 min at RT and immunostained for b-tubulin. Blots were
imaged using a BioRad Western Clarity ECL kit and ChemiDoc XRS imaging system. Protein band
intensities were quantified via densitometry analysis with Quantity One software (Bio-Rad). Raw
intensity values were normalized to the measurement of a b-tubulin loading control and expressed
as the n-fold change to an appropriate control genotype. Antibodies were diluted in PBSTw and
used at the following concentrations: rabbit anti-CSPa 1:20,000 (Enzo Life Sciences Cat# VAP-
SV003E, RRID:AB_2095057); mouse anti-dCSP, 1:20 (DSHB Cat# DCSP-1 (ab49), RRID:AB_2307345;
Zinsmaier et al., 1990); mouse anti-ubiquitin-conjugated protein, 1:2000 (Enzo Life Sciences Cat#
BML-PW8810, RRID:AB_10541840); mouse anti-b-tubulin, 1:1000 (DSHB Cat# E7, RRID:AB_528499);
goat anti-mouse IgG HRP-conjugated, 1:5000 (Thermo Fisher Scientific Cat# 32430, RRID:AB_
1185566; goat anti-rabbit IgG (H+L) HRP-conjugated 1:10,000 (Thermo Fisher Scientific Cat#
A16096, RRID:AB_2534770).
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Hydroxylamine treatment
Adult heads were homogenized in 2% SDS, 100 mM DTT, 60 mM Tris pH 6.8, and then treated with
0.5M hydroxylamine pH 7.0 or 0.5 M Tris pH 7.0 (final concentration) for 24 hr at RT before being
diluted 3-fold using 1x Laemmli buffer. Samples were boiled for 5 min before use for SDS-PAGE.
Immunoprecipitation
Young adult flies (1–3 day post-eclosion) were flash frozen in liquid N2 and stored at  80˚C. Heads
were enriched by brushing frozen heads on double metal sieves under liquid N2. Approximately 100
mL of heads were homogenized in 500 mL IP buffer containing: 1% Triton X-100, 30 mM Tris-HCl (pH
7.2), 150 mM KCl, 0.5 mM MgCl2. Homogenates were repeatedly centrifuged at 22,000 rpm to
remove insoluble debris. The cleared supernatant was incubated with rabbit anti-CSPa at 1:200 (f.c.)
for 1 hr on a rotator at 4˚C and then incubated with 50 mL protein A/G PLUS-Agarose (#sc-2003,
Santa Cruz Biotechnology, Dallas, Texas) for 2 hr at 4˚C. Agarose beads were spun down with a
tabletop centrifuge at 2000 g and the supernatant was removed and stored. The beads were
washed 4x with IP buffer by repeated resuspension and centrifugation. Beads were finally resus-
pended in Laemmli buffer, boiled for 5 min, centrifuged for 2 min and transferred to a fresh tube for
SDS-PAGE.
Electron microscopy
Larvae were rapidly dissected in 4% PFA and then fixed overnight in fresh fixative containing: 3%
glutaraldehyde, 1.5% formaldehyde, 2 mM CaCl2, 0.1M sodium cacodylate, pH 7.3. Samples were
rinsed in 0.1M cacodylate before being fixed with 2% OsO4 for 2 hr. Next, samples were washed
with HPLC grade H2O before being dehydrated with ethanol in a stepped series (30%, 50%, 70%,
90%, 95%,100%) followed by 100% acetone. Tissue was infiltrated with Durcupan ACM plastic
embedding media (#14040, Electron Microscopy Sciences, Hatfield, PA) through progressive mix-
tures with acetone (25%, 50%, 75%, 100%), hardened at 60˚C, trimmed and sectioned with a dia-
mond knife (70 nm). Sections were poststained with 4% uranyl acetate and lead citrate. Images were
obtained on a JEOL 1200EX with an AMT XR80M-B camera running AMT software. For publication,
figures were compiled and prepared with Photoshop CC (Adobe). Contrast and intensity of images
was minimally adjusted. Images were cropped as needed.
Quantification of eye phenotypes
This analysis was essentially done as described by others with some modifications
(Papanikolopoulou and Skoulakis, 2011; Santa-Maria et al., 2015). Briefly, eye phenotypes of 1–2
day old adults were digitally imaged using a stereomicroscope. A semi-quantitative phenotype
assessment was achieved by serially coding the obtained images and blind scoring by several naive
researchers. Each individual eye was given a relative roughness score in comparison with known
scoring classes: (1) normal WT-like eye. (2) Slightly ‘rough’ eye surface, slight dis-colorization, and/or
least reduction in eye size. (3) Rough eye surface, significant dis-colorization, disorganized omma-
tidia, and/or reduced in size. (4) Rougher eye surface; loss of organized ommatidia, malformed and
fused; more pronounced reduction in eye size. (5) Roughest eye surface, most pronounced loss of
organization, and/or most pronounced reduction in eye size. Scores were collected for at least eight
individual flies per genotype.
Data and statistical analysis
Data from at least three independent animals or experimental trials were used for statistical analysis.
Data are represented as mean, and error bars represent SEM. Gaussian distribution of data was
assessed using a D’Agostino and Pearson omnibus or Shapiro-Wilk normality test using Prism soft-
ware (GraphPad Software). Statistical significance was assessed by either a paired or unpaired t test,
Mann-Whitney, or one-way ANOVA (Kruskal-Wallis for non-parametric data) test with appropriate
post-hoc tests using Prism software). P values < 0.05,<0.01, and <0.001 are indicated in graphs with
one, two, and three asterisks, respectively.
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